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Applications of EphB4 receptor specific peptides in targeted cancer imaging and therapy 
        Publication No. ________ 
Miao Huang, M.S. 
Supervisory Professor: Chun Li, Ph.D. 
EphB4 receptors, a member of the largest family of receptor tyrosine kinases, are 
found over-expressed in a variety of tumors cells including glioma cells as well as 
angiogenic blood vessels. Noninvasive imaging of EphB4 could potentially increase 
early detection rates, monitor response to therapy directed against EphB4, and improve 
patient outcomes. Targeted delivery of EphB4 receptor specific peptide conjugated 
hollow gold nanoshells (HAuNS) into tumors has great potential in cancer imaging and 
photothermal therapy. In this study, we developed an EphB4 specific peptide named 
TNYL-RAW and labeled with radioisotope 64Cu and Cy5.5 dye. We also conjugate this 
specific peptide with hollow gold nanoshells (HAuNS) to evaluate targeted photothermal 
therapy of cancers. In vitro, 64Cu-DOTA-TNYL- RAW specifically bind to CT26 and 
PC-3M cells but not to A549 cells.  In vivo, Small-animal PET/CT clearly showed the 
significant uptake of 64Cu-DOTA-TNYL-RAW in CT26 and PC-3M tumors but not in 
A549 tumors. Furthermore, µPET/CT and near-infrared optical imaging clearly showed 
the uptake of the dual labeled TNYL-RAW peptide in both U251 and U87 tumors in the 
brains of nude mice. In U251 tumors, Cy5.5-labeled peptide can bind to EphB4-
expressing tumor blood vessels and tumors cells. But in U87 models, dual labeled 
peptide only could bind to tumor associated blood vessels. Also, Irradiation of PC-3M 
and CT-26 cell treated with TNYL-PEG-HAuNS nanopatilces with near-infrared (NIR) 
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laser resulted in selective destruction of these cells in vitro. EphB4 targeted TNYL-PEG-
HAuNS showed more photothermal killing effect on CT26 tumor model than PEG-
HAuNS did. In summary, tumors with overexpression of EphB4 receptors can be 
noninvasively visualized by micro PET/CT with 64Cu labeled or dual labeled TNYL-
RAW peptide. Targeted delivery of TNYL-RAW conjugated HAuNS into tumors can 
greatly improve the treatment effect of photothermal therapy. The information acquired 
with this study should be advantageous in improving diagnostics and future applications 
in photothermal ablation therapy in clinical. 
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INTRODUCTION 
1. Ephrin receptors 
1.1 Ephrin receptor families 
A tyrosine kinase (erythropoietin-producing human hepatocellular carcinoma 
receptor, Eph receptor) was first discovered by Hirai et al (Science) in 1987. In a 
screening for novel oncogenic tyrosine kinase, Hirai cloned a new gene from a 
carcinoma cell line that was named EphA1 later. They also found that this novel receptor 
tyrosine kinase is up-regulated in tumor versus normal tissues.  Ectopic overexpression 
this kinase can cause the oncogenic transformation of NIH3T3 fibroblasts (1, 2) , which 
suggested the oncogenic function of Eph gene. Later, the corresponding ligand (ephrin 
A1) of Eph A1 receptor was also identified from cancer cell lines.  Eph receptors 
comprise the largest family of vertebrate receptor tyrosine kinases (3). It is now known 
that there are 9 Eph A and 5 Eph B receptors which promiscuously bind to 5 
glycosylphosphatidylinositol (GPI)-linked ephrin-A ligands and GPI-linked 3 ephrin-B 
ligands respectively (4).  But Eph A4 and Eph B2 receptors can also bind to ephrin-B or 
ephrin A5 ligands respectively. EphB4 receptor preferentially binds to ephrin B2 ligand.   
The signal transduction between Ephrin receptors and ephrin ligands is bidirectional. 
Tyrosine kinase activity determined forwarding signal is amplified and propagated in the 
receptor expressing cells and Src family kinase determined reversed signal is propagated 
in ephrin ligand expressing cells.  However, the ephrin ligand-dependent but tyrosine 
kinase independent signaling pathway can also be found at some conditions (5-7). The 
activation of most receptor tyrosine kinases depends on the dimerization of receptors 
once ligand-receptor complex formed. But the activation of Ephrin receptor-ephrin 
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ligand complex is different from the classic activation way of receptor tyrosine kinases 
(8). Multimerization of ephrin ligand molecules on cellular membranes plays an 
important role in Ephrin/Eph function (9, 10).  The signaling pathway of Eph/ephrin 
complex is well understood in the development process of nervous system such as in 
axon plasticity and patterning, which can be explained by repulsive mechanism. The 
Ephrin receptor expressed axons can migrate away from cells that express ephrin ligand 
based on this repulsive mechanism (10). There are lots of signal transduction pathways 
and downstream molecules involved in the Eph/ephrin receptor signaling axis, such as 
JAK/ STAT (11) and AKT/PI3K pathways (12). 
1.2 Biology functions of Ephrin receptor families 
      Ephrin receptors play an important role in numbers of biological processes in normal 
development such as axon guidance, cell migration, cell morphology, cell adhesion, 
invasion, angiogenesis and limb development (13, 14). The signal through Eph receptors 
can influence the cell migration, adhesion and invasion by modifying the structures of 
actin cytoskeleton and affecting the activities of intercellular adhesion molecules and 
integrins (4, 15). Eph receptors are also involved in some specialized cell function such 
as insulin secretion, immune function and bone remodeling (15).   
A lot of evidence has been accumulated to demonstrate that Eph/ephrin axis plays 
significant roles in the development of vasculature. The distinct expression pattern of 
Eph B4 receptor and its ligand ephrin B2 on arterial and venous endothelial cells suggest 
that developing capillary networks may not be uniform structures (16).  The essential 
requirement for tumor growth and survival is the formation of new blood vessels and 
capillaries from pre-existing vasculature networks (angiogenesis). Studies have implied 
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that up-regulation and dysregulation of Eph/ephrin axis signaling pathway involved in 
the new blood vessels formation during the process of the tumor invasion (1, 17, 18) 
Lots of studies have shown that the expression level of Ephrin receptors and ephrin 
ligands is correlated with the cancer progression, invasion, metastasis and the survival 
rate of patients (17-27). For example, EphA2 receptor has been found overexpressed in 
numbers of cancers and its expression level is correlated with the progression of cancer 
and poor prognosis of cancer patients (17-21). Also, among all the cancer types, the 
expression of EphA2 receptor is preferable in the breast and prostate cancers with a 
basal phenotype (22, 23). Studies have shown that up-regulation of Eph A2, A7, A10 
and ligands such as ephrin A2 and B3 is involved in the breast cancer invasion and 
metastasis (24). Up-regulated expression level of Eph receptors and their ephrin ligands 
is correlated with the progression of malignant melanoma (25) Eph A1 not only can 
promote the proliferation of melanoma cancer cells and enhance the cancer cell growth, 
it also can increase the angiogenesis in advanced melanomas (26). Ectopic 
overexpression of Eph A2 can promote progression of benign prostatic epithelial cells 
into more aggressive phenotype (27). 
EphB4 receptors play important roles in a variety of biologic processes, including 
cell aggregation and migration, neural development, embryogenesis and angiogenesis, 
and limb development (13, 28-31). Overexpression of EphB4 receptor, an important 
member of Ephrin family, has been observed in numerous tumor types, including breast 
prostate, bladder, lung, colon, ovarian, and gastric cancers (4, 32-36). Endogenous 
ligand, eprin-B2, can specifically bind to its corresponding receptor EphB4 to promote 
progression and metastasis of various cancers and induce angiogenesis in more advanced 
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cancers. The effect of promotion of tumorigenesis and angiogenesis is mediated through 
the signaling interaction between EphB4 and ephrin B2 ligand. It is interesting to notice 
that some forwarding EphB4 signaling pathway may exhibit the inhibit effect on tumor 
cell proliferation.(37) Xia et al. demonstrated that EphB4 is up-regulated in prostate 
cancer cells and the induction of expression of EphB4 in prostate tumors may undergo 
the transcriptional regulatory effect of pro-survival signaling molecules or through the 
amplification of gene encode EphB4 receptor (38). Furthermore, inhibition of expression 
and oncogenic activity of EphB4 can reduce the survival, migration and invasion of 
prostate cancer cells. Another paper also showed that increased EphB4 activity and 
expression in prostate cancer patients are correlated with the higher grade disease which 
suggested that the expression level of EpHB4 indicate the malignancy of the disease (39). 
In colon cancer, increased expression of the EphB4 gene has been found to play an 
important role in the development of unique tumor phenotype (40). It has been also 
found that EphB4 receptors are expressed at high levels in both tumor cells and blood 
vessels in high-grade gliomas (41).  
1.3 Develop EphB4 Specific peptides for molecular imaging 
As above mentioned, EphB4 is overexpressed in various cancer types including 
prostate, colon and brain tumors (38-41). So it is intriguing to develop a new molecular 
imaging probes targeted for EphB4 receptors. But up to now, there is no peptide based 
imaging probes being developed to detect EphB4 receptors in different tumors.   
The most important thing for molecular imaging is to find a proper molecular target 
to differentiate tumors from normal tissues. There are lots of pathologically abnormal 
processes in cancer that allow us to make molecular imaging probes to target these 
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processes for in vivo detection and functional characterization of tumors. Over the past 
years, a lot of radiolabeled peptides used as nuclear imaging agents have been developed 
for in vivo visualization of solid tumors with overexpressed receptors. For example, 
radiolabeled neuropeptide receptors ligands are suitable molecular targeting probes for 
in vivo visualization of tumors with overexpression of corresponding receptors by 
positron emission tomography (PET) or single photon emission computed tomography 
(SPECT) (42,43). In clinic, small radiolabeled somatostatin peptidyl analogs (molecular 
weight ~1.5 kDa) have been successfully developed for detection and visualization of 
neuroendocrine tumors with overexpression of somatostatin receptors (42, 43). Currently, 
cyclic Arg-Gly-Asp peptide which binds to integrin αvβ3 receptors used for nuclear 
imaging is under clinical investigation (44). Lots of other peptide-based imaging agents, 
such as substance P (45), melanocyte-stimulating hormone analog (46), calcitonin (47), 
atrial natriuretic peptide (48), bombesin/gastrin-releasing peptide, cholecystokinin, 
glucagonlike peptide-1, and neuropeptide-Y, have also been identified and developed for 
in vivo molecular imaging of solid tumors (49). But very few peptides have been 
characterized for noninvasive detection and imaging of prostate cancer, colon cancer and 
gliomas (49).  
Using phage display approach, several 12-mer peptides which specifically bind to 
corresponding Ephrin receptors have been identified by Koolpe et al in  2005 (50). 
Among those peptides, an Ephrin B4 receptor specific peptide (Thr-Asn-Tyr-Leu-Phe-
Ser-Pro-Asn-Gly-Pro-Ile-Ala, TNYL peptide) has been identified from initial screening. 
To optimize this TNYL peptide, the original TNYL peptide has been modified by adding 
a tripeptide moiety (RAW) at the carboxyl terminus based on the information from the 
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sequence alignment. The final product, Thr-Asn-Tyr-Leu-Phe-Ser-Pro-Asn-Gly-Pro-Ile-
Ala-Arg-Ala-Trp (TNYLFSPNGPIARAW, TNYL-RAW) was show to be a strong   
antagonist of EphB4 receptor. This modified peptide inhibited binding of ephrin B2, a 
natural EphB4 binding ligand, to immobilized Eph4 receptor with IC50 around 15 nM 
compared with 150 µM for TNYL peptide (50). In Koolpe’s study, the biotinylated 
TNYL peptide was conjugated to streptavidin-coated quantum dots nanoparticles Qdot 
655 quantum dots (Quantum Dot Corp.) to confirm the targeting effect of this peptide. 
From his study, it has clearly showed that this TNYL conjugated quantum dots can 
specifically bind to COS cells with ectopic expression of Eph B4 receptors or cells with 
endogenous expression of EphB4 (50). Because TNYL-RAW peptide has extremely 
high binding affinity for EphB4 receptors, we tried to investigate whether this peptide 
can be used as molecular imaging agents to noninvasively detect and visualize up-
regulated EphB4 receptors in various tumor models. Furthermore, we conjugated this 
peptide to hollow gold nanoshells (HAuNS) to study the effect of photothermal therapy 
on colon and ovarian cancer model 
2 Multimodal Imaging 
2.1 Nuclear Imaging 
     The first time using of radioactive tracers in the living system was to study the 
transport of radioactive lead in plants was done by Hevesy and Paneth in 1923.  In 1935, 
Hevesy and Chiewitz used radiotracer (P-32) to study the distribution of radioactive P-
32 in rats. Later, Anger invented the first scintigraphic imaging instrument named 
gamma camera in 1956. At the same time, positron imaging was developed too. Now, 
both imaging modalities become standard methods in nuclear medicine filed. The most 
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radioisotopes used in the clinical settings are 99mTc in single photon imaging (SPCET) 
and 18F in positron imaging (PET). Now, PET and SPECT techniques have become the 
standard imaging diagnosis processes for the patients with different diseases. The 
underlying mechanism in nuclear medicine is to use the radiotracers to detect the 
metabolism, biochemical, physiological and pathophysiology process in patients. These 
two imaging modalities can be used alone or combined together to study various 
biological activities in human body such as metabolite rate, binding capacity and 
transport rate. Also they can be used to monitor and detect the expression of enzymes, 
receptors, and transporter as well as their corresponding endogenous analogue such as 
ions, hormones, and enzyme substrates (51-53). Compared with other imaging 
modalities, nuclear imaging has more advantages, such as more sensitive, deep 
penetration into the tissues, and quantitative analysis and process of the image data. But 
there is no perfect single imaging technique. Nuclear imaging can detect abnormal 
physiology, biochemical or metabolic changes in patients but they may provide less 
accurate location and anatomy structure of the human body due to the weak spatial 
resolution of nuclear imaging.  To provide more accurate anatomy location and structure 
information of the patients, multimodality imaging devices such as PET/CT, SPECT/CT, 
and PET/MRI are developed and become more popular in clinical practice. These 
combinations of imaging techniques can provide precise 3-dimensional images of 
biological and anatomical information in patients. Nuclear imaging may require long 
acquisition time of imaging due to the low photon counts. Also, it doesn’t provide 
sufficient resolution details in real time because of the short and finite half-life of the 
radiotracer used (54, 55). Then optical imaging can be an alternative imaging technique. 
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2.2 Optical Imaging 
Optical imaging is a rapidly developing field and attracts lot of interest recently. 
Biomedical optical imaging techniques can be used in various clinical diagnosis and 
molecular biology and substantially affect the outcomes of treatment and prevention of 
cancer (56).  Optical imaging techniques such as fluorescence and bioluminescence 
molecular imaging have lots of advantages compared with traditional imaging 
techniques. First, they can provide high spatial resolution images to reflect both 
functional and structural changes at nano or even femtomolar sensitivity (57). Secondly, 
these techniques are non-invasive, non-radiation, portable and low cost. Third, the 
results of optical imaging can be obtained almost in real time. Fourth, these techniques 
can provide valuable information in both microscopic and macroscopic scales and 
widely applied in almost all biomedical fields. Last but not the least, quantitative 
analysis of optical imaging results can be useful for objective diagnosis and patient 
follow-up.(58-63). Furthermore, these techniques have already been tested in various 
initial clinical situations. For example, it is promising to use hemoglobin and 
deoxyhemoglobin as a biomarker to monitor effective neo-adjuvant chemotherapy in 
breast cancer patients by diffuse optical spectroscopy (64, 65). 
The major limitations of further application of optical imaging techniques in 
clinical settings are the penetration depth due to the strong scattering of optical radiation 
in tissues and strong auto-fluorescence due to the absorbance of the photons by the thick 
and opaque tissues.  The acquired signal can be obscured by above reasons. However, 
recent progress in NIR (near infrared region, 650-900 nm) optical techniques exhibits 
promising in vivo application of optical imaging techniques. First, the detection depth of 
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NIR has been pushed to a few centimeters. Second, NIR molecular imaging technique 
shows lower light absorbance and reduced auto-fluorescence of normal tissues, which 
makes it more suitable for in vivo application (66-70). In our studies, we labeled our 
EphB4 specific peptide TNYL-RAW with NIR fluorophores (Cyanine 5.5 also called 
Cy5.5) for in vivo optical molecular imaging in glioblastoma orthotopic nude mice 
models. Cy5.5 is a fluorescent dye emitting photons in the NIR spectrum and one of the 
members of synthetic cyanine dye family. This dye is water-soluble, and has an 
absorbance maximum of 675 nm and an emission maximum of 694 nm.  
2.3 Importance of Multimodal Imaging 
     Today, various imaging techniques are available for differential diagnosis and 
evaluation of severity of diseases as wells as monitoring the therapeutic response of the 
patients to medical treatments. Among all of these imaging modalities, such as positron 
emission tomography (PET), single photon emission computed tomography (SPECT), 
optical imaging, computed tomography (CT), ultrasound (71) and magnetic resonance 
imaging (MRI), none of them can be used alone to provide sufficient comprehensive 
information necessary for the diagnosis of various disease of patients. Multimodality 
imaging can provide structure and functional information of the disease by two ways. 
One is that images are acquired at different times and then different images are fused 
together by digital imaging processing technique (asynchronous way). Another way 
(synchronous way) is that images are acquired simultaneously and merged 
automatically. It is difficult to fuse images using asynchronous way due to the two 
different scans acquired at separated machines. The best solution to solve the 
inconsistency of the space and time is achieved by using synchronous image acquisition. 
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Currently, lots of multimodality techniques (SPECT/CT, PET/CT, and PET/MR) are 
available in diagnostic imaging fields. The most common techniques among these are 
combinations of high detection sensitivity techniques such as PET and SPECT with CT, 
MRI, and ultrasound that have high spatial resolution. The first prototype of CT-SPECT 
thoracic images of patients was obtained in 1962 (45). Since the commercial 
introduction of SPECT/CT and PET/CT in 1998, the development and use of these 
instruments grows exponentially. Up to now, there are almost no sales of standalone 
PET machines and all PET sales are as part of multimodality systems (72).  
     As we all known, no single imaging modality is perfect. In current study we 
combined the optical imaging technique, one of the most widely used imaging 
techniques in preclinical molecular imaging with nuclear imaging PET/CT, which is the 
most effective clinical imaging modality.   
3 Hollow gold nanoshell 
Optical phenomenon named surface plasmon resonance (SPR) is an important 
characteristic of Au and silver (Ag) containing nanostructures. When these 
nanomaterials are exposed to light, the conduction-band electrons in the metal 
containing nanostructures will collectively oscillate at a resonance frequency relative to 
the lattice of positive ions. Then the nanostructures will absorb the incident light at this 
resonance frequency. The resonance of the solid spherical nanoparticles is about at 400 
nm for Ag and around 520 nm for Au.  The variable peak wavelength of absorbance 
relatively depends on the size or the embedding medium of the nanoparticles. We can 
tune the peak wavelength of SPR from visible to near infrared (NIR) region by changing 
the size, shape, and structure of the nanoparticles.  The novel Au containing 
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nanoparticles termed hollow gold nanospheres (HAuNS) have the unique characteristics 
such as small size (30-60 nm), spherical shape, hollow interior, and strong and tunable 
(520-950 nm) absorption band at NIR region (73, 74).  
Using cobalt (Co) NPs as sacrificial templates to synthesize of HAuNSs with tunable 
interior cavity sizes was first reported by Liang’s group (75). Due to the higher reduction 
potential of the AuCl4-/Au redox pair (0.935 V vs the standard hydrogen electrode [SHE]) 
compared with that of the Co2+/Co redox couple (-0.377 V vs SHE), the Au3+Cl4- can be 
easily reduced to Au (0) atoms once the Co nanoparticles are added into chloroauric acid 
solution. The reaction equation is as this: 3Co+2AuCl4- = 2Au+ 3Co2++8Cl-. The size of 
the final HAuNS product is controlled by the initial size of the Co nanoparticles template 
because the reduced Au atoms are mostly confined to the vicinity of the outer surface of 
the Co template.  The stability of HAuNS is maintained by coating polyethylene glycol 
(PEG) on the surface of the shells. Coating HAuNS with higher molecular-weight (5kDa) 
makes HAuNS much more stable than coating with lower molecular weight (2kDa) PEG 
does. Also HAuNS coated with thioctic-acid-anchored PEG containing two thiol groups 
are more stable in aqueous solution than HAuNS coated with monothiol-anchored PEG.  
4 Photothermal therapy 
Photothermal therapy is a therapeutic method in which photothermal agent is 
introduced to produce heat after the laser energy delivered to the targeted tumors. The 
heat produced by this photothermal effect is far beyond the threshold temperature 
(~330k) which can cause irreversible cell death and kill the tumor cells (76).  This 
therapy modality has attracted a lot of attentions recently because it has lots of 
advantages over the traditional cancer therapies such as fewer side effect, less 
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accumulated toxic effect with repeatedly laser treatments and boosted efficacy of the   
chemotherapy and radiotherapy when combined with photothermal therapy (76-79).       
Nanoparticles with unique optical properties such as gold nanoshells, nanorods, 
nanocages, and hollow nanospheres (80-86) can significantly enhance the efficiency of 
photothermal therapy by integrating these light-absorbing materials into the target tissue 
to mediate the selective photothermal effects. HAuNS have the unique characteristics 
such as small size (30-60 nm), spherical shape, hollow interior, and strong and tunable 
(520-950 nm) absorption band (73, 74), which have the great opportunity to convert 
optical energy into thermal energy for thermal ablation of tumor cells. It is possible to 
deliver thermal energy to the deeper tissue because the SPR absorption peak of HAuNS 
is the easily tunable in the NIR region. Due to the convenient modification of the surface 
of the HAuNS, specific molecular targeting molecules with SH-terminal can be easily 
conjugated to the Au surface of HAuNSs through covalent bonds. Lots of different 
specific targeting molecules such as antibodies, peptides, and low molecular-weight 
compounds have been conjugated to the surface of the HAuNS (73, 87). After 
modification with the specific homing molecules, the HAuNS can be used in targeting 
photothermal therapies in vitro and in vivo. Loo et al. (84) and Lowery  (88) 
demonstrated targeted photothermal killing of human breast cancer cells in vitro when 
irradiated with an NIR laser (820 nm) at 35 W/cm2 for 7 min but no effect on the dermal 
fibroblast which don’t overexpress HER2 receptors on their surface by using HER2 
(human epidermal growth factor receptor 2) specific antibody conjugated nanoshells 
(89). It is well known that one of the most important factors for the cellular uptake of 
nanoparticles is the size of the nanostructures. Nanoparticles larger than 100 nm are 
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difficult for uptake into the cells and may interfere with the normal function of the cells. 
The small particle size (smaller than 20 nm) may be difficult for cells to retain the 
nanoparticles. For in vivo targeting of nanoparticles into tumor tissues, the particle size is 
also a critical factor. It was demonstrated that the smaller size of gold nanoparticles (20-
40nm) coated with PEG has longer blood circulation time than lager gold nanoparticles 
(80 nm). Also with the smaller size, gold nanoparticles has better chance of 
extravasating from tumor-associated blood vessel into the extra-vascular fluid space and 
passively diffused into the tumor tissues. Taken together, the idea size of the particle for 
photothermal therapy in vitro and vivo is between 20 nm and 80 nm. The size of the 
HAuNS we used in this study is around 40 nm. Previous study in our lab demonstrated 
the selective killing EGFR over-expression of  cancer cells A431 in vitro by introducing 
C225 antibody (targeting EGF receptors) conjugated HAuNS into the tumor cells (73). 
This killing effect is mediated through EGFR demonstrated by blocking or non-
conjugated PEG coated HAuNS control studies. Wei et al. (85) conjugated HAuNS with 
a small molecular-weight peptide, [Nle4, D-Phe7] a–melanocyte-stimulating hormone 
(NDP-MSH) for successfully targeted photothermal therapy of melanoma in vitro and 
vivo studies. Our lab previously reported using EphB4 receptor specific TNYL-RAW 
peptide or peptide conjugated polymeric micellar nanoparticles to detect of EphB4 
expression in cancer (90, 91). Therefore, targeting of EphB4 has great potential in cancer 
imaging and therapy.  
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Specific Aims and Significance 
    Early detection of cancer and monitoring the treatment response of cancer patients by 
molecular imaging methods are important components of the differential diagnosis of 
cancer patients and prediction of prognosis of patients. It is desirable to have an imaging 
method to accurately detect and monitor EphB4 status in cancer patients.  Photothemal 
therapy is a novel cancer treatment strategy that kills cancer cells by producing heat after 
the laser energy delivered to the targeted tumors. Introduction of HAuNS into local 
tumor tissues can enhance the photothermal therapy effect. EphB4 is a good targeting 
molecule for specific delivery of HAuNS to tumor tissues.   
    Therefore, the major purpose in my study is: first, to develop a novel targeting peptide 
molecules dual-labeled by Cy5.5 optical dyes and 64Cu nuclear isotopes for early 
detection of tumors with the overexpression of Eph B4 receptors in vivo; Second, 
synthesis and evaluation of photothermal killing effect of EphB4 specific peptide 
conjugated HAuNS on the tumor cells in vitro and vivo. Using this novel imaging agent, 
it allows us to do whole-body scan to visualize and locate tumor by nuclear imaging 
(PET/CT) and followed by fluorescence imaging guided biopsies to define precisely 
extent and region of local tumors. It is first time here to show that EphB4-specific 
peptide could be used as a non-invasive molecular imaging agent for PET/CT or/and 
optical imaging of tumors owing to its ability to bind to EphB4-expressing angiogenic 
blood vessels and or to EphB4-expressing tumors. We believe that translation of this 
discovery from basic science to clinical situation may improve the differential diagnosis 
of cancer patients and affect the outcome of the prognosis of the patients. Conjugation of 
EphB4 specific peptide onto the HAuNS can enhance the delivery HAuNS to local 
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tumor tissues with overexpression of Eph B4 and mediate specific killing effects on 
tumor cells by phothothermal therapy. We hope that our nanoparticles which conjugated 
specific homing molecules can combine imaging and therapeutic functions together for 
cancer diagnosis and treatments in future clinical medicine.  
MATERIALS AND METHODS 
1. Reagents 
All amino acid derivatives and coupling reagents were purchased from Novabiochem 
(San Diego, CA), Bachem (Torrance, CA), and Chem-Impex International (Wood Dale, 
IL). All other chemicals were purchased from Sigma-Aldrich (St. Louis, MO). DOTA-
TA was synthesized in our lab. 64CuCl2 solution was bought from University of 
Wisconsin (Madison, WI). PC-3M cells were gift from Dr. Fiedler (UT MD Anderson 
Cancer Center, TX). CT-26 and A549 cells were purchased from American Type 
Culture Collection (Manassas, VA). U87 cells stably transfected with the luciferase gene 
(U87-Luc) were gift from Dr. Gelovani (UT MD Anderson Cancer Center, TX). U251 
cells were gift from Dr. Shuyun Huang (UT MD Anderson Cancer Center, TX).  Hey A8 
stably transfected with the luciferase gene (HEY A8-Luc) were gift from Dr. Anil Sood 
(UT MD Anderson Cancer Center, TX). RPMI-1640, DMEM/F12 and MEM medium 
were obtained from Gibco (Carlsbad, CA). Calcein AM, Eth-D1 and DAPI were 
purchased from Invitrogen (Carlsbad, CA). PD-10 columns were purchased from 
Amersham-Pharmacia Biotech (Piscataway, NJ). Protein assay kit was purchased from 
Bio-rad (Hercules, CA) D-Luciferin was purchased from Biosynth Chemistry & Biology 
(Staad, Switzerland). Rat anti-mouse CD31 antibody was purchased from Millipore 
(Billerica, MA). Recombinant EphB4/Fc chimera, phycoerythrin-conjugated rat 
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antihuman EphB4 monoclonal antibody, and rabbit anti-EphB4 antibody were purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA). Goat anti-rabbit antibody conjugated 
with near-infrared dye was purchased from Li-COR. DOTA was obtained from 
Macrocyclics. The Biacore sensor chip CM5, amine coupling kit, HBSEP running buffer 
(0.01 M 4-(2-hydroxyethyl)- 1-piperazineethanesulfonic acid [HEPES], pH 7.4; 0.15 M 
NaCl; 3 mM ethylenediaminetetraacetic acid [EDTA]; and 0.005% [v/v] surfactant P20 
solution), and regeneration buffer were purchased from Biacore, Inc. 
2. General Procedures for the peptide synthesis 
Solid phase syntheses of peptide were performed on the automatic peptide 
synthesizer Prelude (PTI, Tucson, AZ) using Rink resin (Novabiochem). 5 × 1.5 mL of 
dimethylformamide (DMF)/methylene chloride (CH2Cl2) was used to wash the resin 
(0.05 – 0.1 g). 3 × 1.5 mL of 20% piperidine/DMF was used to remove 
fluorenylmethyloxycarbonyl (Fmoc) groups for 5 min each. Three-fold excesses of 
Fmoc-amino acids, diisopropylcarbodiimide (DIC), and HOBt (1-hydroxybenzotriazole) 
were used in 3 mL of DMF/CH2Cl2 for coupling procedure. This procedure was repeated 
once. Resins were washed with 3 × 3 mL of DMF/CH2Cl2 after coupling and 
deprotection steps. Resins were washed with 3 × 3 mL of CH2Cl2 and treated with 
trifluoracetic acid (TFA): triisopropylsilane: H2O (95:2.5:2.5) for 15 min each once the 
procedure of peptide chain enlongation was finished. The combined filtrates sat at room 
temperature for 1-2 hr, and the volumes were reduced in a vacuum. Peptides were 
precipitated in ice-cold ethyl ether, washed 2 times with ethyl ether and collected by 
centrifugation. After drying, peptides were purified by reverse-phase high-performance 
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liquid chromatography (RP-HPLC) on an Agilent 1200 system (C-18, Vydac, 10 × 250 
mm, 10 µm; Santa Clara, CA).  
Solution phase reaction was used to synthesize DOTA and fluorescein 
isothiocyanate (FITC)-coupled TNYL-RAW (Figure 3A) peptides followed by HPLC 
purification.  For conjugation of Cy5.5 or/and DOTA to TNYL-RAW peptides, a 
solution of Cy5.5-NHS (1eq) and peptide TNYL-RAW or DOTA-NHS (1eq) and 
peptide TNYL-RAWK (Figure 8A) in dimethylformamide and DIPEA (10/1) were 
stirred at room temperature overnight. A lysine group was introduced to the peptide 
sequence before simultaneous conjugation of Cy5.5 and DOTA to the peptide due to the 
C-terminal amide group in original peptide sequence. Before introduction of lysine 
group, a glycine linker amino acid was added at c-terminal to minimize the effect on 
binding affinity of peptide after modification of sequence. After the solvent was 
removed under vacuum, the residual was purified by reverse-phase HPLC, eluted with a 
0.01-M solution of NH4OAc in water and acetonitrile, and lyophilized. The peptides 
were identified by high-resolution electrospray ionization mass spectrometry (HRMS-
ESI) spectra acquired in the positive ion mode. This was done on an Agilent 1100 Series 
LC/MSDTOF instrument equipped with a Vydac C18 column (4.6 x 250 mm, 7 µm, 300 
Å) (Anaheim). For synthesis of PEG-TNYL-SATA (Figure 15A) peptide, the peptide 
and heterodifunctional poly (ethylene glycol) (PEG) precursor, N-hydroxysuccinimidyl-
PEG-S-acetylthioacetate (NHS-PEG-SATA; molecular weight 5,000, figure 15A) was 
conjugated together, through peptide’s α-amine group of threonine residue and activated 
ester in NHS-PEG-SATA. The sulfhydryl group on the other terminus of TNYL-PEG-
SATA was released by treatment with 0.05 M hydroxylamine in PBS.  
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3.   Synthesis of HAuNS 
       HAuNS were synthesized according to the method of Schwartzberg et al. with 
minor modifications (70). Briefly, 2500 µL of sodium borohydride (1 M) was added into 
1000 mL of deoxygenated aqueous solution of sodium citrate (2.8 mM) and cobalt 
chloride (0.4 mM) to synthesize cobalt template nanoparticles. The clear and slightly 
pink solution turned brown after adding sodium borohydride, which indicated reduction 
of Co (II) and the formation of cobalt nanoparticles. The solution was left to stay at room 
temperature for 45 min under constant gas flow of argon until complete hydrolysis of the 
sodium borohydride. In a different vial, bubbling with argon gas was used to 
deoxygenate 600 mL chloroauric acid (0.04 mM) solution. Then, 800 mL of cobalt 
nanoparticle solution was transferred to the chloroauric acid solution under argon 
protection and magnetic stirring. Gold ions were immediately reduced by cobalt onto the 
surface of cobalt nanoparticles while at mean time cobalt was oxidized to cobalt oxide. 
Any remaining cobalt core was further oxidized by air, resulting in the final formation of 
HAuNS.  
4. Conjugation of TNYL-PEG-SATA to HAuNS 
The reaction scheme of conjugation of TNYL-PEG-SATA to the surface of HAuNS 
is shown in Figure 15B. Briefly, TNYL-PEG-SATA (1mg/mL, 200 µL) solution was 
treated with hydroxylamine (50mmoL/L, 50µL) in total volume of 500µL PBS 
containing 10mM of EDTA (pH 7.0) before conjugation to HAuNS. The reaction 
mixture was stirred at room temperature for about 2 h. Then the product (TNYL-PEG-
SH) was purified by passing through a PD-10 column (Amersham-Pharmacia Biotech, 
Uppsala, Sweden) and eluted with PBS (pH 7.4). Therefore, the purified TNYL-PEG-SH 
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was added into HAuNS (2x1012particles/mL) solution and stirred at room temperature 
for about 6 hours. Then PEG-SH (5 mg/mL, 0.4 mL) was added into mixture and 
allowed to react overnight at room temperature. The final product (TNYL-PEG-HAuNS) 
was purified by centrifuging at 8,000 rpm for 15 minutes and the pellet was resuspended 
with PBS. This process was repeated twice to remove excess peptide and free PEG-SH 
molecules. The purified TNYL-PEG-HAuNS was sent to the core facility in Baylor 
College of medicine to do the amino acid analysis. PEG-SH was conjugated to HAuNS 
similarly to above procedure to give PEG-HAuNS, which was used as a nonspecific 
control. 
5. Photothermal Effect of different HAuNS solutions 
The photothermal effect of HAuNS solutions was measured as previously described.  
Briefly, the laser was a continuous wave GCSLX-05-1600m-1 fiber-coupled diode laser 
(Newport model 840-C). A 5-m 600-Am core BioTex LCM-001 optical fiber was used 
to transfer laser light from the laser unit to the target. The laser spot size of the lens 
mounting at the output could be changed by changing the distance from the output to the 
target. The output power was separately calibrated by a handheld optical power meter 
(Newport model 840-C) and was found to be 1 W for a spot diameter of 3.5 mm (8 
W/cm2) and a 2-amp supply current. NIR laser light (808 nm) was delivered through a 
quartz cuvette containing the nanoshells (100 µL) to heat HAuNS and its derivatives. A 
thermocouple was inserted into the solution perpendicular to the path of the laser light to 
measure the temperature changes mediated by NIR laser light. The temperature was 
measured over a period of 15 min. 
6. In vitro Photothermal Ablation of Tumor cells 
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PC-3M, CT-26 and Hey A8-Luc cells were seeded onto a 96-well plate with a density 
of 1x105 cells per well one day before the experiment. Cells were washed three times 
with culture medium without phenol red and FBS. The following groups were used: NIR 
laser alone, TNYL-PEG-HAuNS plus laser, PEG-HAuNS plus laser, TNYL-PEG-
HAuNS with excess TNYL-PEG peptide (blocking group) plus laser. For treated with 
HAuNS, cells were incubated with PEG-HAuNS or TNYL-PEG-HAuNS (100 µL, 
2x1011 particles/mL) at 37oC for 2 hours. For blocking group, cells were co-incubated 
with TNYL-PEG-HAuNS with excess amount of TNYL-PEG peptide. After incubation, 
cells were washed three times with PBS to remove nonspecific binding of or unbound 
HAuNS. Cells were re-cultured in DMEM/F12 medium without phenol red 
supplemented with 10%FBS. Then cells were irradiated with near IR-region laser light 
centered at 808nm at an output power 40 W/cm2 for 5 min (15PLUS laser, Diomed) and 
incubated at 37 oC for additional 24 h. The diode laser was coupled to a 1-m, 2-mm core 
fiber, which delivered a circular laser beam of 2mm in diameter to cover the central area 
of the microplate well. Power calibration was done automatically. Cells were washed 
three times with HBSS (Hank’s balanced salt solution) and stained with calcein AM 
(green color) for detection of viable cells and Eth-D1 (red color) for detection of dead 
cells 24 h after the laser treatment. Cells were visualized under the Zeiss Axio 
Observer.Z1 fluorescence microscope (Carl Zeiss MicroImaging GmbH, Germany). 
7. Radiolableing 
For Radiolabeling of DOTA-TNYL-RAW and peptides, 64CuCl2 (74–148 MBq [2–4 
mCi]) in 0.1 M sodium acetate (pH 5.2) was added to 10 µg aqueous solution of DOTA-
TNYL-RAW or Cy5.5-TNYL-RAW-DOTA. The reaction mixture was incubated at 
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70°C for 1 h. The progress of the reaction was monitored by reversed-phase high-
performance liquid chromatography (RP-HPLC) with a radiodetector. EDTA was added 
into the solution to terminate the reaction. The 64Cu-labeled peptide was further purified 
by RP-HPLC on an Agilent 1100 system (C-18, Vydac; 4.6 · 250 mm, 10 mm) and 
eluted at a linear gradient of 10%–90% acetonitrile in a 0.1% aqueous trifluoroacetic 
acid solution over 35 min at a flow rate of 1.0 mL/min. 64Cu-DOTA-TNYL-RAW and 
64Cu-DOTA-TNYL-RAW-Cy5.5 peptides were collected in 1- to 2-mL fractions. The 
solvent was then removed, reconstituted in saline and passed through a 0.22-mm filter 
for using in the animal experiments. Natural copper chloride (natCuCl2) was used to 
synthesize natCu-DOTA-TNYL-RAW under identical conditions. High-resolution 
electrospray ionization mass spectrometry was used to confirm the identity of natCu-
DOTA-TNYL-RAW. 64Cu-DOTA-TNYL-RAW was co-injected with natCu-DOTA-
TNYL-RAW into the HPLC system, which was equipped with both ultraviolet and 
radiodetectors to confirm its identity. 
For conjugation of 64Cu to nanoparticles, DOTA-TA (1 mg/mL, 10 µL) was mixed 
with 1 mL aqueous solution of HAuNS (4×1012 particles/mL) for 4 h at room 
temperature. The following conjugation of TNYL-PEG-SH and/or PEG-SH to AuNS, 
and purification was the same as above described. For radiolabeling, aliquots of TNYL-
PEG-HAuNS-DOTA) or PEG-HAuNS-DOTA (4×1012 particles/mL, 0.5 mL) in 0.1 
mol/L sodium acetate solution (pH 5.5) were mixed with an aqueous solution of 64CuCl2 
(~2 mCi) for 30 min. The radiolabeled nanoparticles were then purified by centrifugation 
at 8,000 rpm for 5 min and washed three times with PBS. The radiolabeling efficiency 
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and the stability of labeled nanoparticles were analyzed using instant thin layer 
chromatography (ITLC). 
8. Immobilization of EphB4 receptor to sensor chip 
10 mM sodium acetate buffer at pH 4.5 was used to dilute the stock solution (100 
µg/ml, in PBS) of EphB4/Fc into three different concentrations of solutions (25, 12.5, 
and 6.25 µg/ml). The diluted solution was immobilized to a CM5 sensor chip using the 
amine coupling reaction following manufacturer-provided procedures (BIACORE). 
Briefly, the surfaces of the chips in flow cells (FC)-1, -2, -3, and -4 were activated by 
exposing them to a mixture of 200 mM N-ethyl-N’-dimethylaminopropyl carbodiimide 
(EDC) and 50 mM N-hydroxysuccinimide (NHS) for 7 min. FC-1 was used as a 
reference surface and deactivated by directly injecting of 1 M ethanolamine at pH 8.5 for 
7 min. The other three flow cells were injected with 25 µg/ml, 12.5 µg/ml, and 6.25 
µg/ml EphB4/Fc solutions respectively and followed by injection of 1 M ethanolamine 
to block the remaining activated ester groups on the surface. Before injection of samples, 
the chip was allowed to stabilize for at least 2 h in HBSEP running buffer.The 
sensogram of immobilized EphB4 on CM-5 sensor chips were shown in figure 2A. The 
mechanism of coupling of EphB4 receptor to CM5 sensor chip is shown in figure 2B.  
9.  Surface Plasmon Resonance (SPR) Assay of Receptor Binding Affinity 
Binding assays were performed at 25ºC in HBSEP running buffer. The peptides were 
diluted in HBSEP buffer, filtered, degassed, and injected at concentrations between 1.6 
nM and 800 nM at a flow rate of 30µl/min. The injection time of peptides into the 
HBSEP buffer was 4 min, followed by a 4-min dissociation period. After each binding 
cycle, the chips were regenerated using a 1-min pulse of 10 mM glycine (pH 2.2). Each 
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cycle consisted of a 1-min waiting period to allow monitoring of the baseline binding 
stability for subtraction of bulk effects caused by changes in the compositions of buffer 
or nonspecific binding. Because we performed double referencing, all samples were 
additionally injected onto an uncoated reference surface, including a sample of the 
running buffer, which was also tested on the EphB4/Fc coated flow cell. Data were 
evaluated with BIAevaluation software (version 3.0, BIACORE), applying a simple 1:1 
binding mass transfer model. The obtained sensorgrams were fitted globally over the 
whole range of injected concentrations for both the association and dissociation phases. 
Equilibrium dissociation constants were then calculated from the rate constants (KD = 
koff/kon) (90).  
10. Stable transfecetion of Luciferase gene into U251 cells (U251-Luc) 
     U251 cells were seeded in the 6-well plates (5x105 cells/well) and incubated 
overnight at 37°C in a humidified incubator in an atmosphere of 5% CO2 24h before the 
experiment. 2ml DMEM/F12 medium (without FBS) with 50ul Cignal™ Lenti Positive 
Control (luc) viral particles (8µg/mL polybrene) were added into the well after culture 
medium was removed. The plates were gently swirled to mix the solution. 6‐8 hours 
later, the viral supernatant (from the first infection) from the wells was removed and the 
cells were re-infected with 2mL of fresh supernatant (with polybrene 8µg/ml). The next 
day, viral supernatant was removed and DMEM/F12 with 10% FBS was added back to 
the cells. 72 hours after incubation, the cells were sub-cultured into 100mm dishes and 
the puromycin (1µg/ml) was added into cells to select the cells expressing luciferase. 
After 1 week selection, luciferase activity of the selected positive cells was tested by 
Xenogen IVIS-200 Optical in Vivo Imaging System (Caliper Life Sciences).  
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11. Fluorescence and Darkfield microscopy 
      For peptide binding study, PC-3M, CT26, or A549 cells were seeded (1x105/well) in 
Lab-Tek II–chambered slides (Nalge Nunc International) supplemented with 
DMEM/F12 medium plus 10% FBS 24h before the experiment.  The cells were 
incubated with 100 µL of phenol-free DMEM/F12 culture medium with addition of 10 
µM FITC-TNYL-RAW or scrambled FITC-scTNYL-RAW (AGPFNTYLRINAWSP) 
for 20 min at room temperature. For the blocking experiment, 10 µM FITC-TNYL-
RAW and 1 mM TNYL-RAW were simultaneously added to the cells and incubated for 
half an hour at 37°C. For detection of EphB4 expression, cells were fixed with 4% 
paraformaldehyde for 20 min and washed 3 times with PBS, then incubated with 50 µL 
of phycoerythrin-conjugated rat anti-human EphB4 monoclonal antibody (R&D Systems) 
or rabbit anti-human EphB4 polyclonal antibody (1:100 dilustion) in PBS at 4°C 
overnight. For polyclonal antibody, goat anti-rabbit antibody conjugated with Alexa 
flour 488 was used as secondary antibody (1:500 dilutions). The cell nuclei were 
counterstained with DAPI. After washing with PBS, the slides were mounted and 
visualized under an Axiovert Z.1 fluorescent microscope (Zeiss).  
For nanoparticles binding study, PC-3M and CT-26 Cells were seeded at density of 
2x 105 per well in 24 wells plate with coverslip in each well 24 h before experiment. The 
culture medium was removed and cells were washed with HBSS twice. Then the culture 
medium without FBS was added back into the cells. 2x1011particles/mL of PEG-HAuNS 
or TNYL-PEG-HAuNS were added into each well and incubated for 2 hours at 37 ºC. 
For blocking group, excess amount of free TNYL-PEG peptide (1 mg) was added with 
TNYL-PEG-HAuNS into cells as a control. After incubation, cells were washed with 
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cold PBS 3 times and counterstained with 4, 6-diamidino-2-phenylindole (DAPI; Sigma, 
Saint Louis, MO). Then the cells were fixed in 4% paraformaldehyde solution in 20 min 
at room temperature and washed with PBS 3 times. Cells on coverslip were mounted 
with mounting medium (Dako, CA) onto slides. The slides were examined under a 
fluorescence microscope with a dark-filed condense to determine the binding of TNYL-
PEG-HAuNS particles to tumor cells. Cells without adding nanoparticles were used as 
background control.  
12. Cell binding  
       For peptide uptake study, CT26, PC-3M, and A549 cells were grown in 6-cm Petri 
dishes as described before (25). The culture medium was replaced with 2 mL 
DMEM/F12 culture medium without FBS containing 64Cu-DOTA-TNYL-RAW (~1.48 
MBq/mL [~20µCi/mL], 100 nM). Cells were incubated with radiolabeled peptides at 
room temperature for 30, 60, or 120 min. For the blocking experiment, 64Cu-DOTA-
TNYL- RAW peptide (~1.48 MBq/mL [~40µCi/mL], 100 nM) was co-incubated with 
TNYL-RAW (10 µM) under the same conditions. Thereafter, the monolayer of cells 
were scraped and transferred into 5-mL tubes. The tubes were briefly stirred at a vortex 
mixer, and 100 µL of the cell suspension were transferred into a micro-centrifuge tube 
containing 500 µL of a 75:25 mixture of silicon oil (density, 1.05; Sigma-Aldrich) and 
mineral oil (density, 0.872; Acros). The mixture was centrifuged at 14,000 rpm for 5 min. 
After the tubes were snap-frozen in liquid nitrogen, the bottom tips containing the cell 
pellet were cut off. The cell pellets and supernatants were counted by a Packard Cobra 
Quantum g-counter (GMI) seperately. The protein content in a 100-µL of cell 
suspension was quantified using the Bio-Rad protein assay kit according to the 
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manufacturer’s protocol. The radioactivity in the cell pellets and medium was counted, 
and the data were expressed as activity ratios of the cell pellet to the medium 
([counts/min/mg of protein in pellet]/[counts/min/mg of medium]). The experiments 
were performed in pentaplicate.  
       For Nanoparticles uptake study, PC3-M and CT-26 cells were seeded on 6 cm petri 
dish at 1x106 densities in MEM or RPMI-1640 (Gibco, Carlsbad, CA) supplemented 
with 10% fetal bovine serum and antibiotics (100 units/mL penicillin, 0.1mg/mL 
streptomycin, Biochrom AG, Holliston, MA). Cells were allowed to grow at 37oC in a 
humidified atmosphere with 5% CO2 overnight. On the experiment day, cell culture 
medium was replaced with 2mL of fresh medium without FBS containing 2x1011 
particles/mL 64Cu-TNYL-PEG-HAuNS or 64Cu-PEG-HAuNS (~2.0 MBq/mL) and cells 
were incubated for 2 h. After incubation, the supernatant were removed and the cells 
were washed with cold PBS for three times to remove non-specific binding of particles. 
The cells were then trypsinized and resuspended in culture medium. The cell suspension 
(100 µL) and the supernatants (100 µL) were counted with a gamma counter (Perkin-
Elmer, Waltham, Massachusetts). The protein concentration of 100 µl cells was 
quantified in s separate experiment using the Bio-Rad protein assay kit according to the 
manufacture’s protocol. Activity of the cell suspensions to supernatant ([cpm/µg of 
protein in cells]/ [cpm/µg of medium] were calculated and plotted against time. The 
experiments were performed in pentaplicate. 
13. Animal Models 
All animal studies were performed under the guidelines and approval of the MDACC 
Institutional Animal Care and Use Committee. Athymic nude mice (4–6 wk old, both 
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sexes) were obtained from Harlan Laboratories. For mice subcutaneous tumor model, 
CT26, PC-3M, and A549 cells were grown in DMEM/F12 supplemented with 10% FBS, 
penicillin (100 IU/mL), and streptomycin (100 mg/mL) (Invitrogen) at 37 ˚ C in a 
humidified atmosphere with 5% CO2. The cells were harvested by trypsinization. After 
centrifugation of the cell suspension at 5,000 rpm for 5 min, the culture medium was 
aspirated and the cell pellet was resuspended in PBS for subcutaneous injection in the 
right front leg of each mouse. When the size of tumor reached around 1 cm in diameter, 
small-animal PET/CT and biodistribution analysis were performed. 
For orthotopic tumor model, Male nude mice (8-10 weeks old; Charles River 
Laboratories) were used for the imaging experiments. Human glioblastoma U87 cells 
(1x106) or U251 (3x106) stably transfected with the luciferase gene (U87-TGL) were 
implanted in the brain of nude mice (1 mm right to and 2.5 mm behind the bregma, and 
3 mm of depth) with a small animal stereotaxic device (David Kopf Instruments). The 
mice were received intravenous injection of D-luciferin (4 mg/kg, Biosynth Chemistry & 
Biology, Staad, Switzerland) 10 days after tumor inoculation. For ovarian cancer Hey-
A8 tumor model, 1 million tumor cells were intraperitoneally injected into nude mice. 
Tumor burden as measured by luciferase activity was measured by using Xenogen IVIS-
200 Optical in Vivo Imaging System (Caliper Life Sciences) for bioluminescence 
imaging (BLI). The bioluminescence signal generated in mice was imaged and 
quantified using the LIVINGIMAGE V.2.11 software and IGOR image analysis 
software (V.4.02 A, WaveMetrics). Region of interest (ROI) was manually selected and 
signal intensity expressed in terms of number of photons/sec. 
14. Small-Animal PET/CT 
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      Mice bearing PC-3M tumors (n=4 EphB4-positive), CT26 tumors (n =4; EphB4-
positive), or A549 tumors (n=4; EphB4-negative) were imaged with small-animal 
PET/CT at various times after intravenous injection of 7.4 MBq (200 µCi) of 64Cu-
DOTA-TNYLRAW (0.5–1µg). For the blocking group, the tumor-bearing mice (n=2) 
were co-injected with 7.4 MBq (200 µCi) of 64Cu- DOTA-TNYL-RAW and cold 
TNYL-RAW peptide at a concentration of 50 µg/mouse. Images were acquired using an 
Inveon PET/CT system (Siemens). The spatial resolution of the PET system is 
approximately 1.4 mm. Tumor-bearing mice were anesthetized with isoflurane (2% in 
oxygen) and placed prone. The CT parameters were as follows: x-ray voltage, 80 kVp; 
anode current, 500 mA; and exposure time of each of the 360 rotational steps, 300–350 
ms. Images were acquired at 1, 4, and 24 h after intravenous administration of 64Cu-
DOTA-TNYL-RAW. Images were reconstructed using the 2-dimensional ordered-
subsets expectation maximization algorithm. PET and CT image fusion and image 
analysis were performed using Inveon Research Workplace (Siemens Preclinical 
Solutions). In order to calculate tumor voxel intensity, an irregular 3-dimensional region 
of interest (ROI) was manually drawn to cover the whole tumor on CT and then copied 
to the corresponding PET images. A circular ROI was drawn on the muscle of the legs. 
An ROI was also drawn on a standard (radiotracer solution containing 1% of the 
injection dose) placed along with the animals. The mean activities within the ROI of the 
tumor and muscle were calculated in an IRW workstation (Siemens).  
    Mice bearing U251 tumors (n=4 were imaged with small-animal PET/CT at various 
times after intravenous injection of 7.4 MBq (200 µCi) of 64Cu-Cy5.5-TNYLRAW-
DOTA (0.5–1 µg). For the blocking experiment, the U251 tumor-bearing mice (n =3) 
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were coinjected with 7.4 MBq (200 µCi) of 64Cu-Cy5.5-TNYL-RAW-DOTA and cold 
Cy5.5-TNYL-RAW-DOTA peptide at a dose of 50 µg/mouse. Images were acquired 
using an Inveon PET/CT system (Siemens). Tumor-bearing mice were anesthetized with 
isoflurane (2% in oxygen) and placed prone. The CT parameters were as follows: x-ray 
voltage, 80 kVp; anode current, 500 mA; and exposure time of each of the 360 rotational 
steps, 300–350 ms. Images were acquired at 1 and 24 h after intravenous administration 
of 64Cu-Cy5.5-TNYL-RAW-DOTA. Images were reconstructed using the 2-dimensional 
ordered-subsets expectation maximization algorithm. PET and CT image fusion and 
image analysis were performed using Inveon Research Workplace (Siemens Preclinical 
Solutions). For tumor voxel intensity calculation, an irregular 3-dimensional region of 
interest (ROI) was manually drawn corresponding to PET images. A circular ROI was 
drawn on the normal brain part An ROI was also drawn on a standard (radiotracer 
solution containing 1% of the injection dose) placed along with the animals. The mean 
activities within the ROI of the tumor and normal brain were calculated in an IRW 
workstation (Siemens). 
15.  Micro-PET imaging  
CT-26 tumors were grown subcutaneously in the right thigh of the female nude 
mice (20-25 g; Harlan Sprague Dawley, Indianapolis, IN) by injection of 1x 106 tumor 
cells suspended in PBS. One week after inoculation, when tumor reached approximately 
8-10 mm in diameter, mice were divided into 2 groups (n=3). Mice (group 1) were 
intravenously injected 64Cu-TNYL-PEG-HAuNS and mice (group 2) were injected with 
64Cu-PEG-HAuNS (1x1011 particles/mouse, 200 µCi/mouse; 0.2 mL). The mice were 
anesthetized with 2% isoflurane and placed in the prone position, and micro-PET 
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imaging was acquired at 1 h, 6 h, and 24 h after injection of the radiolabeled 
nanoparticles using an R4 microPET unit (Siemens Medical Solutions USA, Inc.), which 
has an approximate resolution of 2 mm in each axial direction. Mice were maintained 
under anesthesia with 1%–2% isoflurane, and a heating lamp was used to maintain their 
body temperature during acquisition. Small-animal PET images were reconstructed with 
the ordered-subsets expectation maximization algorithm using 16 subsets and 4 
iterations. 
16. Near Infrared (NIR) Optical Imaging 
       Mice bearing U87 tumors (n =4) or U251 tumors (n=4) were imaged with Xenogen 
IVIS-200 Optical in Vivo Imaging System (Caliper Life Sciences) at various times after 
intravenous injection of 10µg of 64Cu-Cy5.5-TNYL-RAW-DOTA or 64Cu-Cy5.5-
scramble peptide. Cy5.5 fluorescence filter set (excitation 615-665 nm, emission 695-
770 nm, background 580-610 nm) was applied. After mice were sacrificed, the 
fluorescence signal of different organs and tumors were analyzed by Living Imaging 
LIVINGIMAGE V.2.11 software and IGOR image analysis software (V.4.02 A, 
WaveMetrics). Region of interest (ROI) was manually selected and signal intensity 
expressed in terms of number of photons/sec. 
17. In Vivo Biodistribution studies 
       For nude mice subcutaneous tumor models, nude mice bearing PC-3M, CT26, and 
A549 xenografts (n =4/group) were injected with 0.74 MBq (20 µCi, 50 ng) of 64Cu-
DOTA-TNYL-RAW peptide to evaluate the biodistribution of the radiotracer. For the 
blocking experiment, the tumor-bearing mice (n=4) were coinjected with 0.74 MBq (20 
µCi) of 64Cu-DOTA-TNYL-RAW and 200-fold cold TNYL-RAW peptide. The animals 
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were sacrificed at 4 and 24 h after injection. The organs of interest were excised and 
weighed and their radioactivity was counted by an automatic g-counter (GMI). The 
stomach and intestines were not emptied before radioactivity measurements. The 
percentage of injected dose per gram of tissue (%ID/g) was calculated by dividing 
the %ID organ by the weight of the organ. Values were expressed as mean±SD. 
Mice bearing CT-26 tumors were prepared as described previously. When the tumor 
reached 4-6 mm in diameter, the mice were randomly assigned into 2 groups (n=6). 
Mice (group 1) were intravenously injected 64Cu-TNYL-PEG-HAuNS and mice (group 
2) were intravenously injected with 64Cu-PEG-HAuNS (1x1011 particles/mouse, 20 
µCi/mouse; 0.2 mL). Mice were killed by CO2 overexposure 24 h after injection of 
radiolabeled nanoparticles. Blood, heart, liver, spleen, kidney, lung, stomach, intestine, 
muscle, bone, brain, and tumor tissues were removed and weighed, and the radioactivity 
was measured with a gamma counter (Perkin-Elmer, Waltham, Massachusetts). Uptakes 
of 64Cu-labeled HAuNS in various organs were expressed as percentages of injected 
dose per gram of tissue (%ID/g). 
For HEY A8-Luc intraperitoneal model, 1x 106 cells were intraperitoneally injected 
into mice. Tumor burden on mice was monitored by bioluminance activity. After tumor 
reached to 0.2 to 1cm, the he mice were randomly assigned into 2 groups (n=6). Mice 
(group 1) were intravenously injected 64Cu-TNYL-PEG-HAuNS and mice (group 2) 
were intravenously injected with 64Cu-PEG-HAuNS (1x1011 particles/mouse, 20 
µCi/mouse; 0.2 mL). Mice were killed by CO2 overexposure 24 h after injection of 
radiolabeled nanoparticles. Blood, heart, liver, spleen, kidney, lung, stomach, intestine, 
muscle, bone, brain, and tumor tissues were removed and weighed, and the radioactivity 
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was measured with a gamma counter (Perkin-Elmer, Waltham, Massachusetts). Uptakes 
of 64Cu-labeled HAuNS in various organs were expressed as percentages of injected 
dose per gram of tissue (%ID/g). 
18. Autoradiography and Optical Imaging 
Mice brains containing U251 tumors were harvested at the end of the imaging 
session were snap-frozen and sectioned into 4-µm sections. The sections were 
photographed and exposed onto BAS-SR 2025 Fuji phosphorus films. The film was 
scanned with a FLA5100 Multifunctional Imaging System (Fujifilm Medical Systems 
USA, Stamford, CT). After autoradiography study, optical images of the sections were 
acquired by scanning at 800 nm using an Odyssey infrared imaging system (LI-COR 
Biosciences, Lincoln, NE). 
19. H&E staining and Immunohistochemical Analysis 
      For nude mice subcutaneous tumor models, after the small-animal PET/CT studies 
were completed, the mice were sacrificed and the tumors were excised, snap-frozen, and 
cut into 4-µm sections. For immunohistochemical analysis, frozen tumor sections were 
fixed in 4% paraformaldehyde solution for 20 min at room temperature and washed with 
PBS 3 times. Tumor sections were blocked with 10% goat serum for 30 min at room 
temperature, and the slides were then incubated with rabbit anti-EphB4 antibody (U-200, 
1:100 dilution) in PBS at 4˚C overnight. After incubation with primary antibody, slides 
were washed with PBS 3 times and incubated with secondary goat antirabbit antibody 
conjugated with Alexa Flour 488 (1:500 dilution; Invitrogen). Slides were washed again 
in PBS and counterstained with DAPI. Microphotographs were taken under a Zeiss 
Axiovert Z.1 fluorescence microscope with the same conditions and displayed at the 
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same scale to make sure that the relative brightness observed in the images reflected the 
difference in EphB4 expression level. 
     After the small-animal PET/CT and near infrared optical studies were completed, the 
mice were sacrificed and tumors in mice brains were excised, snap-frozen and cut into 4-
mm sections. For immunohistochemical analysis, frozen tumor sections were fixed in 
4% paraformaldehyde solution for 20 min at room temperature and washed with PBS 3 
times. Tumor sections were blocked with 10% goat serum for 30 min at room 
temperature, and the slides were then incubated with rabbit anti-EphB4 antibody (U-200, 
Santa Cruz Biotech, CA, 1:100 dilution) and rat anti-mouse CD31 (Millipore,Billerica, 
MA, 1;50 dilution) in PBS at 4˚C  overnight. After incubation with primary antibody, 
slides were washed with PBS 3 times and incubated with secondary goat anti-rabbit 
antibody conjugated with Alexa Flour 488 (1:500 dilution; Invitrogen) and donkey anti-
rat antibody conjugated with Alexa Flour 594 (1:500 dilution; Invitrogen). Slides were 
washed again in PBS and counterstained with DAPI. Frozen blocks were sent to the core 
histology facility in MD Anderson Cancer Center for H&E staining. Microphotographs 
were taken and visualized by a Zeiss AxioCam MRc5 color camera. 
20. Photothermal Ablation of Cancer Cells with TNYL-PEG-HAuNS in Vivo 
      Nude mice were inoculated subcutaneously with 1x106 CT-26 cells in the right side 
of the rear legs 10 days before the experiment. When tumor growth reached 7-10 mm in 
diameter, mice were randomly assigned into 4 groups (n=5). Mice (group 1) were 
intravenously injected with TNYL-PEG-HAuNS (2x1012 per mouse, 200 µL); Mice 
(group 2) were injected with PEG-HAuNS (2x1012 per mouse, 200 µL); Mice (group 3) 
were injected saline as control; Mice (group 4) were not received any treatment. The 
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tumors from groups 1, 2, 3 were irradiated with NIR laser at 3W/cm2 for 3 minutes 24 h 
after injection of nanoparticles. The mice were killed 24 h after the laser treatment, then 
the tumor was removed and cryosectioned into 5-µm sections for H&E staining. The 
slides were visualized under a Zeiss Axio Observer.Z1 fluorescence microscope. The 
images were taken using a Zeiss AxioCam MRc5 color camera.  
    Nude mice were inoculated with 1x106 Hey-A8-Luc cells intraperitaneally 14 days 
before experiments. Tumor growth was monitored by luciferase activity. Mice were 
randomly assigned into 3 groups.  Mice (group 1) were injected with PEG-HAuNS 
(2x1012 per mouse, 200 µL). Mice (group 2) were injected saline as control. Mice (group 
3) were not received any treatment. The abdomens of mice bearing tumors were cut and 
open, and then tumors were exposed. Because tumors grown in mice belly as multiple 
nodules, so some nodules were used as internal control. 24 h after injection of 
nanoparticles, the tumors from groups 1 and 2 were irradiated with NIR laser at 2W/cm2 
for 3 minutes. The mice were killed 24 h after the laser treatment, and then the tumors 
and normal tissue around the tumors treated with laser were removed and cryosectioned 
into 5-µm sections for H&E staining. The slides were visualized under a Zeiss Axio 
Observer.Z1 fluorescence microscope. The images were taken using a Zeiss AxioCam 
MRc5 color camera. 
21. Statistical Analysis 
    Statistical analysis was performed with GraphPad Prism v4.0 software (La Jolla, CA). 
Unless otherwise stated, group comparisons were made using standard ANOVA 
methods. Groups with P < 0.05 were considered statistically significant.  
RESULTS 
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1. Synthesize and evaluate 64Cu-labeled TNYL-RAW peptides for PET 
imaging of EphB4 receptors in prostate and colon cancer xenograft models 
1.1 Chemistry, Radiochemistry, and Stability 
Figure 1A shows the structure of natCu/64Cu-DOTA-TNYL-RAW. The reaction 
scheme for the synthesis of natCu/64Cu-DOTA-TNYL-RAW is shown in Figure 1B. 
TNYL-RAW, DOTA-TNYL-RAW or FITC-TNYL-RAW was eluted as a single peak 
with a retention time of 13.8 min, m/z =1,705.7764 for [M+H] + (C80H117N22O20, 
calculated [M+H] +: 1,705.8814); 12.6 min, m/z =2,092.0554 for [M+H] + 
(C96H143N26O27, calculated [M+H]+: 2,092.0616) and 15.6 min, m/z= 2,094.9003 for 
[M+H] + (C101H128N23O25S, calculated [M+H] +: 2,094.9172) respectively. The formation 
of the natCu (II)-labeled complex natCu-DOTA-TNYL-RAW was confirmed by mass 
spectrometry (Figure 1C), with m/z=1,076.9957 for [M+Cu]2+ (C96H143CuN26O27, 
calculated [M+Cu]2+: 1,076.9917). natCu-DOTA-TNYL-RAW (ultraviolet detector) and 
64Cu-DOTA-TNYL-RAW (radiodetector) had almost identical retention times (12.5 and 
12.6 min, respectively) under the similar HPLC condition (Figure 1D.) The 
radiochemical purity of 64Cu-DOTA-TNYL-RAW (the ratio of the main product peak to 
all peaks) was determined by HPLC to be more than 95%. The specific activity of 64Cu-
DOTA-TNYL-RAW used in the in vitro and in vivo experiments was typically 7.4–14.8 
MBq/nmol (0.2–0.4 Ci/mmol) at the end of synthesis.  The stability of 64Cu-DOTA-
TNYL-RAW was checked in culture medium (DMEM with 10%FBS) for up to 24 h at 
37 ˚ C. Around 30% of the 64Cu-DOTA-TNYL-RAW was degraded after 2 h of 
incubation in culture medium at 37˚C.  
 Figure 1A.  Structure of 
peptides  (peptide sequence: 
(90)) 
 
Fig  1B. Reaction scheme of synthesis of 
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Figure 1C.  Electrospray ionization mass spectrometry spectrum of natCu-DOTA-
TNYL-RAW (Reprinted with permission of (90)) 
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Figure 1D. Radio-HPLC chromatogram of 64Cu-DOTA-TNYL-RAW (tR = 12.6 min) 
compared with chromatogram of natCu-DOTA-TNYL-RAW (tR = 12.5 min) with UV 
detection at 210 nm.  (Reprinted with permission of (90)) 
 
1.2 Binding Affinity of TNYL-RAW and DOTA-TNYL-RAW-DOTA, NatCu-
DOTA-TNYL-RAW and scramble peptides 
      Figure 2A shows the sensogram of successful coating of EphB4 receptor on CM-5 
sensor chip. Figure 2B shows the mechanism of coupling of EphB4 ligand to the surface 
of the CM5 sensor chip. Figure 2C shows representative sensorgrams obtained from SPR 
analyses of TNYL-RAW and DOTA-TNYL-RAW, NatCu-DOTA-TNYL-RAW and 
scramble peptides with fitting curves obtained using a global 1:1 mass transfer model. 
The corresponding binding kinetics and affinity data are summarized in Table 1. TNYL-
RAW had a KD of 3.06 nM. Conjugation of DOTA to the N terminus of the peptides 
decrease the binding affinity, the KD value of the TNYL-RAW increased to 23.3 nM. 
Interestingly, chelation of Cu2+ to the DOTA-TNYL-RAW restored the binding affinity 
of peptides, with the KD value back to around 1.98 nM. Because we didn’t see response 
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of scramble peptide to EphB4 receptor on SPR assay (Figure 2B), there was no 
detectable binding ability of scramble peptides to the coated receptors.  
 
 
Figure 2A. Sensogram of successful coating of EphB4 receptor on CM-5 sensor chip/ 
EDC/NHS was used to activation of chip. Ethnolamine was used to saturate unbound 
site on the sensor chip. 
 
 
 
Figure 2B. Mechanism of coupling of EphB4 ligand to the surface of CM5 sensor chip 
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Figure 2C. SPR sensorgrams of TNYL-RAW and DOTA-TNYL-RAW-DOTA, NatCu-
DOTA-TNYL-RAW and scramble peptides on sensor chips coated with EphB4. 
Peptides were injected as ten 2-fold-concentration series from 1.6 to 800 nM and were 
analyzed in duplicate binding cycles. Datasets (shown in black) are overlaid with curves 
fit to 1:1 mass transfer interaction model (red lines). Vertical axes in response units 
represent binding of each peptide to immobilized EphB4. (Reprinted with permission of 
(90)) 
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Analyte   kon [M-1S-1] koff [s-1]            KD [M]                   χ2
TNYL-RAW 4.26×105 1.3×10-3 3.06×10-9 0.155 
DOTA-TNYL-RAW 1.10×105 2.56×10-3 2.33×10-8 0.281 
Nat Cu-DOTATNYL- 
RAW 
6.89×106 1.31×10-2 1.89×10-9 1.86 
     
Table 1. Association, Dissociation Rates and KD of different TNYL-RAW peptides and 
derivatives interacting with immobilized EphB4 receptors obtained from SPR Analysis. 
 
1.3 Fluorescence microscope 
Previous papers have shown that the EphB4 receptors are overexpressed in prostate 
and colon cancer cells (38, 40). Immunofluorescence study confirmed the positive 
expression of EphB4 receptor on the surface of CT-26 and PC-3M cells after stained 
with phycoerythrinconjugated rat antihuman EphB4 monoclonal antibody, but not on the 
surface of EphB4-negative A549 cells (Fig3B). The structure details of FITC-TNYL-
RAW peptides were shown in Fig 3A. FITC-TNYL-RAW peptides (green color) 
strongly bind to the surface of PC-3M and CT-26 cells, but not on the EphB4-negative 
A549 cells. The specific binding of FITC-TNYL-RAW peptides to the CT-26 and PC-
3M cells were confirmed by the blocking or scramble peptide binding study which 
showed that the binding of these FITC labeled peptides was efficiently blocked by co-
incubation with excess amount of TNYL-RAW peptides and there was no detectable 
binding of FITC labeled scramble peptides binding to those EphB4 positive peptides.  
 Fig 3A The structure details of FITC
Figure 3B. Fluorescence photomicrographs of PC
RAW (10 µM, green) or scrambled peptide FITC
min at room temperature. Cells were also stained with phycoerythrin
EphB4 antibody (red) for expression of EphB4 receptors. For blocking experiment, 
FITC-TNYL-RAW (10 µM) was coincubated with 
were counterstained with DAPI (blue). Bar =20
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1.4 In vitro radioisotope binding assay 
      
64Cu-DOTA-TNYL-RAW peptides were highly uptake by CT-26 and PC3-M cells. 
The uptake of radiolabeled peptides of these cells was increased with time from 30min 
to 2 hours. The specific binding of these peptides can be efficiently blocked by adding 
excess amount of cold peptide TNYL-RAW and the total binding was decreased by 
around 10 fold at all time points (Figure 4A and 4B). 
 
Figure 4A.  Uptake of 64Cu-DOTA-TNYL-RAW in EphB4-positive PC-3M cells. Cell-
to medium uptake ratio is expressed as (counts/ min/mg of protein in 
pellet)/(counts/min/mg of medium). 64Cu-DOTA-TNYL-RAW showed increased uptake 
over time in PC-3M cells. * Indicates the p value <0.005. (Reprinted with permission of 
(90)) 
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Figure 4B. Uptake of 64Cu-DOTA-TNYL-RAW in EphB4-positive CT-26 cells. Cell-to 
medium uptake ratio is expressed as (counts/ min/mg of protein in 
pellet)/(counts/min/mg of medium). 64Cu-DOTA-TNYL-RAW showed increased uptake 
over time in PC-3M cells. * Indicates the p value <0.005. (Reprinted with permission of 
(90)) 
 
1.5 Small animal Micro PET/CT 
Figure 5A showed the micro PET/CT results of nude mice bearing tumors after tail 
vein injection of 64Cu-DOTA-TNYL-RAW.  CT-26 tumors were clearly visualized at 1h 
and 4 h after injection of 64Cu labeled TNYL-RAW peptides. But for PC-3M tumors, the 
highest uptake of 64Cu-DOTA-TNYL-RAW time point was 24 h after injection of 
radiolabeled peptides. There was very low uptake of 64Cu-DOTA-TNYL-RAW in 
EphB4 negative A549 cells. According to the ROI calculations described in the above 
methods, the uptake of 64Cu-DOTA-TNYL-RAW in CT26 tumors was rapid, from 
1.3 %ID/g at 1h post injection to 2.6 %ID/g at 4 h post injection, respectively.  But the 
level of tumor radioactivity in CT26 tumor was barely detectable at 24 h after injection 
of radio tracer (Fig. 5A). The uptake values of 64Cu-DOTA-TNYL-RAW in PC-3M 
tumors were 1.4, 3.2, and 3.6 %ID/g at 1, 4, and 24 h after injection, respectively.  The 
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For EphB4-negative A549 tumors, the uptake of 64Cu-DOTA-TNYL-RAW was at the 
level of 1.7, 1.5, and 1.2 %ID/g at 1, 4, and 24 h after intravenous injection of 
radiotracer. The summary of the different uptake of 64Cu-DOTA-TNYL-RAW in CT26, 
PC-3M and A549 tumors at different time points was shown in table 2. We found that 
the time point of highest uptake value of radio tracer is different in CT26 (4h post 
injection) and PC-3M (24h post injection) tumors in vivo based on our micro PET/CT 
results, so we chose different time points to do blocking study for CT26 (4h post 
injection) and PC-3M (24h post injection) tumors. Uptake of 64Cu-DOTA-TNYL-RAW 
in CT26 tumors was blocked by co-injection of excess amount of cold TNYL-RAW 
peptides (50µg/mouse) (micro PET/CT images were taken at 4h post injection of radio 
tracers). The specific uptake of radiotracer in PC-3M tumors was efficiently blocked by 
co-injection of excess amount of cold TNYL-RAW peptide (50µg/mouse) (micro 
PET/CT images were taken at 24h post injection of radio tracers). Based on the 
calculations of ROI, the co-injection of cold peptides caused about 77% and 81% 
reduction in 64Cu-DOTA-TNYL-RAW uptake in CT-26 and PC-3M tumors respectively. 
(ROI of tumor (non-block)-ROI of tumor (block)/ ROI of tumor (non-block)). 
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Figure 5A.  Representative small-animal PET/CT imaging of mice bearing CT26, PC-
3M, and A549 tumors after tail vein injection of 64Cu-DOTA-TNYL-RAW (n=4). 
Arrows indicate different tumors (PC-3M, CT26 and A549). (Reprinted with permission 
of (90)) 
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Figure 5B. Representative micro PET/CT images showed the uptake of 64Cu-DOTA-
TNYL-RAW was blocked in CT26 tumors at 4 h and in PC-3M tumors at 24 h after co-
injection of 64Cu-DOTA-TNYL-RAW with cold TNYL-RAW (50µg/mouse). Arrows 
indicate tumors. (Reprinted with permission of (90)) 
 
 
 
 
Table 2 Shows the summary of summary of the different uptake of 64Cu-DOTA-TNYL-
RAW in CT26, PC-3M and A549 tumors at different time points. 
 
1.6 In vivo biodistribution 
Figure 6A shows the biodistribution of 64Cu-DOTA-TNYL-RAW at 24 h after 
radiotracer administration in nude mice bearing PC-3M or A549 lung tumors. There was 
significantly higher uptake of 64Cu-DOTA-TNYL-RAW in PC-3M tumors than in A549 
tumors (0.84 %ID/g vs. 0.44 %ID/g, SD 5 0.09 and 0.09, respectively, P<0.000015). 
1.2%1.5%1.7%A549
3.6%3.2%1.4%PC-3M
N/A2.6%1.3%CT26
24h4h1hTumor Type
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Figure 6B shows the biodistribution results of the mice bearing CT-26 tumor at 4 h post 
injection of   64Cu-DOTA-TNYL-RAW. The tumor The tumor-to-muscle ratio was 
reduced 56.7% in CT-26 tumors at 4 h and 47.6% in PC-3M tumors at 24 h after co-
injected 64Cu-DOTA-TNYL-RAW with cold TNYL-RAW peptide compared with 
injection of 64Cu-DOTA-TNYL-RAW only (Fig. 6C).  
 
Figure 6A. Biodistribution of 64Cu-DOTA-TNYL-RAW in mice bearing PC-3M and 
A549 tumors at 24 h after injection. Data are presented as %ID/g and are expressed as 
mean±SD (n =4). (Reprinted with permission of (90)) 
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Figure 6B. Biodistribution of 64Cu-DOTA-TNYL-RAW in mice bearing CT-26 tumors 
at 4 h after injection. Data are presented as %ID/g and are expressed as mean±SD (n 
=4). (Reprinted with permission of (90)) 
 
 
Figure 6C. Tumor-to-muscle-uptake ratio in mice bearing CT-26 or PC-3M tumors. In 
blocking group, mice were co-injected 64Cu-DOTA-TNYL-RAW (7.4 MBq [200 µCi]) 
with cold TNYL-RAW peptide (20 µg/mouse). Data are presented as mean±SD (n=6). 
(Reprinted with permission of (90)) 
 
 
 
1.7 Immunofluorescence study on tumor sections 
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Immunofluorescence staining confirmed the expression of EphB4 on the CT26 and 
PC-3M tumors, but there was no expression of EphB4 receptor on A549 tumor cells. 
The ex vivo immunofluorescence results was similar to the pattern of in vitro binding 
study. 
 
 
Figure 7. Immunofluorescence analysis of EphB4 expression in CT26, PC-3M, and 
A549 tumor sections excised after the imaging studies. Rabbit anti-human EphB4 
antibody and goat anti-rabbit antibody conjugated with Alexa Flour 488 were used. 
Bar=100 µm. (Reprinted with permission of (90)) 
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2. Evaluate 64Cu- and Cy5.5-labeled TNYL-RAW peptides for dual PET/optical 
imaging of EphB4 receptors in orthotopic glioma models 
2.1 Synthetic scheme of peptide Cy5.5-TNYL-RAW and Cy5.5-TNYL-RAWK-
DOTA  
     The peptide synthesis and introduction of Cy5.5 were carried out on solid phase 
(Figure 8A). For synthesis of Cy5.5-TNYL-RAW-DOTA, the DOTA was introduced in 
solution phase after cleavage of Cy5.5-TNYL-Raw peptide from the resin. After 
cleavage and purification of those peptide by HPLC, they were characterized by 
Electrospray ionization) mass spectrometry (ESI-MS). m/z [M+H]+ = 2604.0366; 
calculated for Cy5.5-TNYL-RAW, C121H159N24O33S4: 2604.0384 and  m/z [M+H]+ = 
3175.3224; calculated for Cy5.5-TNYL-RAW-DOTA, C145H200N31O42S4:  3175.3350. 
The radiochemical purity, defined as the ratio of the main product peak to all peaks, was 
determined by HPLC to be >95%. The specific activity of Cy5.5-TNYL-RAWK-DOTA-
64Cu used in the in vitro and in vivo experiments was typically 7.4-14.8 MBq/nmol (0.2-
0.4 Ci/µmol) at the end of synthesis. The structure details of Cy5.5-TNYL-RAW and 
Cy5.5-TNYL-RAW –DOTA were shown in Fig 8B and 8C. 
 Figure 8A. Synthetic scheme of peptide Cy5.5
DOTA 
 
Figure 8B.  Structure details of 
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-TNYL-RAW and Cy5.5-TNYL
Cy5.5-TNYL-RAW 
 
-RAWK-
 
 Figure 8C. Structure details of 
2.2 Binding Affinity of Cy5.5
      Figure 9 shows representative sensorgrams obtained from SPR analyses of TNYL
RAW (Figure 1A), DOTA-TNYL
Cy5.5-TNYL-RAWK-DOTA
obtained using a global 1:1 mass transfer model. The corresponding binding kinetics and 
affinity data are summarized in 
of Cy5.5 to the N terminus and/or DOTA to the C terminus of the peptide didn’t 
significantly change the KD
nM respectively).  
53 
and Cy5.5-TNYL-RAWK-DOTA 
-TNYL-RAW and Cy5.5-TNYL-RAWK-DOTA
-RAW (Figure 1A), Cy5.5-TNYL-RAW
 (Figure 8C) and scrambled peptide, with fitting curves 
Table 3. TNYL-RAW had a KD of 3.06 nM. Conjugation 
 value of original TNYL-RAW peptide (1.27 nM and 1.01 
 
 
-
 (Figure 8B), 
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Figure 9. SPR sensorgrams of DOTA-TNYL-RAW, Cy5.5-TNYL-RAW, Cy5.5-
TNYL-RAWK-DOTA and Cy5.5-scrambled peptide on sensor chips coated with 
EphB4. Peptides were injected as ten 2-fold-concentration series from 1.6 to 800 nM and 
were analyzed in duplicate binding cycles. Data sets (shown in black) are overlaid with 
curves fit to 1:1 mass transfer interaction model (red lines). Vertical axes in response 
units represent binding of each peptide to immobilized EphB4. 
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Analyte kon [M-1S-1] koff [s-1] KD [M] χ2 
DOTA-TNYL-RAW 1.1×105 2.56×10-3 2.33-8 0.28 
Cy5.5-TNYL-RAW 4.15×106 5.28×10-3 1.27-9 4.37 
DOTA-TNYL-
RAWK-Cy5.5 
1.86×106 1.87×10-3 1.01-9 5.67 
TNYL-RAW 4.26X105 1.3X10-3 3.06-9 0.155 
 
Table 3. Association, Dissociation Rates and KD of different TNYL-RAW peptides and 
derivatives interacting with immobilized EphB4 receptors obtained from SPR Analysis. 
 
2.3 Detection of brain tumor growth by luciferase imaging 
       10 days after U87-Luc and U251-Luc tumor cells implanted in nude mice brain, 
Tumor burden as measured by luciferase activity was assessed using Xenogen IVIS-200 
Optical in Vivo Imaging System. Figure 10 clearly showed the luciferase activity in the 
brain area of the nude mice in both tumor models, and there is no other detectable signal 
in spinal cord area, which confirmed that the tumors were successfully grown in the.  
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Figure 10.  Representative Lucifease imaging of U251 and U87 glioblastoma on 
orthotopic mice. Figure 10 shows luciferase signal of U251 and U87 10 days after tail 
vein injection of luciferin. 
 
2.4  Optical Imaging of U251 and U87 tumors in the brain 
Figure 11A showed Cy5.5 optical imaging of U251 and U87 tumor in the brain.  24 
hours after tail vein injection of Cy5.5-TNYL-RAW-DOTA, U87 or U251 tumor 
implanted in nude mice brain was clearly visualized. To confirm the specific uptake of 
Cy5.5-TNYL-RAW-DOTA to tumor, Cy5.5 conjugated scrambled peptide was used. In 
figure 11B, U87 tumors in the brain of nude mice were clearly seen on optical imaging 
at 1 h, 4 h and 24 h time point after tail vein injection of Cy5.5-TNYL-RAW-DOTA, but 
there was little signal being detected in the nude mice brain after tail vein injection of 
Cy5.5-scramble peptide at same time points.  
U87 U251
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Figure 11A.  Representative Cy5.5 optical imaging of U251 and U87 glioblastoma on 
orthotopic mice. Cy5.5 near-infrared fluorescence optical imaging U251 and U87 
tumors 24 hours after tail vein injection of 64Cu-Cy5.5-TNYLRAW-DOTA.     
U87 U251
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Figure 11B. Representative near-infrared (NIR) fluorescence optical images of U87 after 
tail vein injection of Cy5.5-TNYLRAW-DOTA or Cy5.5-scramble, imaging taken at 
various time points.  Figure 11B upper panel shows the NIR optical imaging of U87 
tumors at 1h, 4h and 24 hours after tail vein injection of Cy5.5-TNYLRAW-DOTA.  
Figure 10B lower panel shows the NIR optical imaging of U87 tumors at 1h, 4h and 24 
hours after tail vein injection of Cy5.5-scramble peptides. 
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2.5 Ex vivo analysis of the fluorescence signal intensities of dissected tissues 
      Figure 12A and 12B shows the biodistribution of Cy5.5-TNYL-RAW-DOTA or 
Cy5.5-scramble-DOTA in mice bearing U87 tumors by ex vivo analysis of the 
fluorescence signal intensities of dissected tissues.  High fluorescence activity was found 
in mice liver, kidney, stomach and intestine. Compared with fluorescence densities in 
two groups at different time points, it clearly showed that U87 tumor has significantly 
higher uptake of Cy5.5-TNYL-RAW-DOTA than that of Cy5.5-scramble-DOTA did. 
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Figure 12A. Representative near-infrared (NIR) fluorescence optical images of various 
tissues obtained from the mouse at the end of the imaging sessions. Images were taken at 
1h, 4h and 24 hours after i.v. injection of 64Cu-Cy5.5-TNYL-RAW-DOTA or 64Cu-
Cy5.5-scramble peptides.  
Cy5.5-TNYL-RAW
1 h
4 h
24 h
Cy5.5-Scramble
1 h
4 h
24 h
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Fig 12B.  Biodistribution at 24h after i.v. injection of different peptides, obtained using 
the fluorescence intensity measurement method, plotted as photon flux per gram of 
tissue. All data are expressed as mean ±standard deviation (n=4). 
 
2.6 Nuclear Imaging of tumors in the brain 
Figure 13A shows small-animal PET/CT of both coronal and transverse slices that 
contain U87 tumor. Tumors were clearly visualized at 1 and 24 h after tail vein injection 
64Cu-Cy5.5-TNYLRAW-DOTA. Figure 13B compares small-animal PET/CT images 
obtained in the presence and absence of a large excess of cold Cy5.5-TNYLRAW (50 
µg/mouse) at 1h and 24h after radiotracer injection in U251 tumor bearing mice. AT 1h 
and 24 h after injection of radiotracer, the U251 tumors were clearly visualized 
compared with barely detectable signal in blocking group. In U251 tumor models, the 
co-administration of cold Cy5.5-TNYL-RAW-DOTA caused a 57% reduction in the 
Cy5.5-scramble
Cy5.5-TNYL-RAW
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ratio of 64Cu-Cy5.5-TNYLRAW-DOTA accumulations in tumors versus normal brain 
based on tumor voxel intensity calculation from PET/CT image (Figure 13C). 
 
Figure 13A. Micro PET/CT images of mice bearing a U87 after intravenous 
administration of 64Cu-labeled Cy5.5-TNYL-RAW-DOTA. The mice bearing a U87 
tumortumor received 64Cu-labeled Cy5.5-TNYL-RAW-DOTA. 
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Figure 13B. Micro PET/CT images of mice bearing a U251 after intravenous 
administration of 64Cu-labeled Cy5.5-TNYL-RAW-DOTA. The mice bearing a U251 
tumor received 64Cu-labeled Cy5.5-TNYL-RAW-DOTA or excess amount of cold 
Cy5.5-TNYL-RAW-DOTA peptide as blocking group.  
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Figure 13C. Compared tumor voxel intensity / normal brain voxel intensity between 
64Cu-labeled Cy5.5-TNYL-RAW-DOTA and blocking group based on calculation from 
an irregular 3-dimensional region of interest (ROI) manually drawn corresponding to 
PET images. * Indicates p value <0.05 
 
 
 
 
 
*
64Cu-Cy5.5-TNYL-RAW-DOTA Block
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Figure 13 D. Representative autoradiograph, fluorescence and H&E staining images of 
excised brain tissue containing U251 tumors.  
 
2.7  Immunohistochemistry 
        Figure 14 shows the immunofluorescence results of the expression of EphB4, 
binding site of Cy5.5 labeled TNYL-RAW peptide on mice brain section containing 
implanted tumor. In figure 14 upper panel, expression of EphB4 (green color) was 
detected on both U251 tumor cells and tumor associated blood vessel (red color CD31 
staining). The binding of 64Cu-Cy5.5-TNYL-RAW-DOTA was also correlated with 
EphB4 expression on tumor section, which was also detected on both tumor cells and 
tumor associated vessels. From figure 14 lower panels, the expression of EphB4 was 
only detected on tumor-associated blood vessel but not on tumor cells, which was also 
corresponding to 64Cu-Cy5.5-TNYL-RAW-DOTA binding site on tissue sections. 
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Figure 14. Fluorescence microscopy of mice brains including implanted U87 or U251 
tumors excised after imaging studies. The mice bearing a U251 or U87 tumor were 
injected intravenously with 64Cu-labeled Cy5.5-TNYL-RAW-DOTA peptides. Signal 
from Cy5.5-loaded TNYL-RAW-DOTA was pseudocolored purple. EphB4 (green) was 
stained with rabbit anti-human EphB4 antibody and Alexa Flour 488-conjugated goat 
anti-rabbit immunoglobulin. CD31 (red), which is the marker of the endothelial cells of 
tumor associated vessel were stained with rat anti-mouse CD 31 antibody and Alexa 
flour 594-conjugagted donkey anti-rat antibody.  Cell nuclei were counterstained with 
DAPI (blue). Bar=100 µm. 
 
3. To develop and evaluate EphB4 specific peptide conjugated HAuNS for 
photothermal ablation therapy of colon cancer in vitro and vivo 
3. 1 Synthesis and Characterization of TNYL-PEG-HAuNS 
       The structure of TNYL-PEG-SATA peptide was shown in Figure 15 A. The 
reaction scheme of the conjugation of TNYL-PEG-SATA peptide the surface of HAuNS 
is shown in Figure 15B. Figure15C is the resonance absorbance of these different AuNS 
particles. This data showed that there were no significant changes in the resonance 
absorbance of HAuNS after conjugation with TNYL-PEGS-SATA or PEG-SH. The 
absorbance peaks of different HAuNS solutions are still around at 800nm which is 
suitable for phothothermal therapy at near infrared region. Calculation of the number of 
U251
U87
EphB4 (receptor)CD31 Cy5.5-TNYL DAPI/CD31/EphB4/TNYL-Cy5.5
 peptide per particle was based on the result of amino acid analysis from the core facility 
in Baylor College of Medicine.  Each particle has app
its surface. As confirmed by instant thin
of TNYL-PEG-HAuNS was about 98% after purification by centrifuge.
 
Figure 15A. structure details of 
Figure 15B.  Reaction scheme for the conjugation of TNYL
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-PEG-SATA to HAuNS.
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Figure 15C.  The resonance absorbance of these different HAuNS particles (AuNS, 
PEG-HAuNS, TNYL-PEG-HAuNS) 
 
Colon and prostate cancer model for photothermal therapy  
3.2 Fluorescence and dark field microscope 
      EphB4 receptors are overexpressed in PC-3M and CT-26 cells [38]. Figure 16 shows 
the dark field images of PC-3M human prostate cancer cells and CT26 murine colon 
cancer cells incubated with TNYL-PEG-HAuNS. The uptake of TNYL-PEG-HAuNS 
was high in EphB4-positive PC-3M and CT-26 cells, while there was very low uptake of 
PEG-HAuNS in both cells, suggesting that the high uptake of the TNYL-PEG-HAuNS 
was mediated through EphB4. Moreover, the specific uptake of TNYL-PEG-HAuNS in 
PC-3M and CT-26 cells could be efficiently blocked by excessive amount of TNYL-
PEG-SATA peptides 
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Figure 16.  Fluorescence microphotographs (dark field) and radioactive uptake study of 
EphB4-positive PC-3M and CT-26 cancer cells after incubation with TNYL-PEG-
HAuNS or PEG-HAuNS. Representative fluorescence and dark field microphotographic 
images.  In right panel, PC-3M cells were incubated with TNYL-PEG-HAuNS (left 
upper) for 2 h; PC-3M cells were incubated with PEG-HAuNS (left middle) for 2 h; PC-
3M cells were co-incubated with TNYL-PGL-HAuNS and excess amount of TNYL-
PEG (Left lower) for 2 h. In left panel, CT-26 cells were incubated with TNYL-PEG-
HAuNS (left upper) for 2 h; CT-26 cells were incubated with PEG-HAuNS (left middle) 
for 2 h; CT-26 cells were co-incubated with TNYL-PGL-HAuNS and excess amount of 
TNYL-PEG (Left lower) for 2 h. Signal from dark field is pseudocolored green. Cell 
nuclei were counterstained with DAPI (blue). Scale bar=50 µm.  
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3.3 In vitro radioisotope binding assay 
Cell uptake of TNYL-PEG-HAuNS was also evaluated by the radioactivity count 
method, and the result was consistent with the results obtained by dark field fluorescence 
microscopy. PC-3M cells and CT-26 showed significantly higher uptake of 64Cu-labeled 
TNYL-PEG-HAuNS than the uptake of 64Cu-labeled PEG-HAuNS (Figure 17). The 
above cell binding results confirmed that TNYL-PEG-HAuNS can specifically bind to 
EphB4 positive cancer cells.  
 
Figure 17.  Radioactive uptake study of cells incubated with 64Cu labeled TNYL-PEG-
HAuNS or PEG-HAuNS. PC-3M cells (left) were incubated with 64Cu labeled TNYL-
PEG-HAuNS (dark gray) or TNYL-HAuNS (light gray) for 2 h; CT-26 cell (right) were 
incubated with 64Cu labeled TNYL-PEG-HAuNS (dark gray) or TNYL-HAuNS (light 
gray) for 2 h. The data were expressed as cpm/µg protein in cell pellet over cpm/µg 
medium and presented as mean ± standard deviation (n=5). * Indicates statistically 
significance with P<0.01 
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3.4 In vitro photothermal ablation of cancer cells 
    To compare the photothermal effect of TNYL-PEG-HAuNS with original HAuNS 
and PEG-HAuNS, above three nanoparticle solutions were exposed to an 8 W/cm2 near 
infrared-region laser respectively. The temperature of all solutions was increased from 
27 ºC to 75 ºC at the concentration of 4x1011 particles/mL. There was no significant 
difference in the changes of temperature among these nanoparticles (Figure 18). These 
data suggested that HAuNS still can be an efficient photothermal coupling agent after 
conjugation with TNYL–PEG-SATA or PEG-SH. Figure 18 and 19 show that most of 
PC3-M and CT-26 cells treated with TNYL-PEG-HAuNS plus NIR laser irradiation (40 
W/cm2 for 5 min) were not stained by calcein AM dye but stained for Eth-D1, which 
suggested that majority of cells were dead after NIR laser treatment. In contrast, cell 
viability has no changes after treatment of PEG-HAuNS plus laser, and laser only. The 
photothermal killing ability of TNYL-PEG-HAuNS was significantly abolished after 
adding excess amount of TNYL-PEG-SATA. 
 Figure 18. Heating of aqueous TNYL
exposed to NIR light centered at 808 nm at 8 W/cm
72 
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Figure 19.  CT-26 cells viability after various treatments, most of cells were dead after 
treatment with TNYL-PEG-HAuNS plus NIR laser. Live cells were stained with calcein 
AM and dead cells were stained for Eth-D1.  Scale bar=100 µm. 
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Figure 20. PC-3M cells viability after various treatments. Most of cells were dead after 
treatment with TNYL-PEG-HAuNS plus NIR laser. Live cells were stained with calcein 
AM and dead cells were stained for Eth-D1.  Scale bar, 100 µm. 
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3.5 Micro-PET Imaging    
       Figure 21 showed the micro-PET images of the mice bearing CT-26 tumors 
acquired at 1, 6, and 24 h after intravenous injection of 64Cu-TNYL-PEG-HAuNS or 
64Cu- PEG-HAuNS. Micro-PET images revealed that the uptake of 64Cu-TNYL-PEG-
HAuNS in the tumor was gradually accumulated from 1 h to 24 h.  The tumor was 
clearly visualized at 24 h after the injection of 64Cu-TNYL-PEG-HAuNS. There were 
fewer signals detected in the tumors of mice injected with 64Cu- PEG-HAuNS. 
Figure 21. Micro PET imaging of mice bearing a CT-26 tumor after intravenous 
injection of 64Cu labeled TNYL-PEG-HAuNS or TNYL-HAuNS. The mice bearing a 
CT-26 tumor were administration of 64Cu labeled TNYL-PEG-HAuNS or PEG-HAuNS. 
Representative micro PET images at 1h, 6h, and 24h after tail vein i.v. injection of 64Cu 
labeled TNYL-PEG-HAuNS and Representative micro PET images at 1h, 6h, and 24h 
after tail vein i.v. injection of 64Cu labeled PEG-HAuNS. 
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3.6 In vivo biodistribution 
      The biodistribution data described in Figure 22 are consistent with the micro-PET 
imaging results. At 24 h after injection, uptake of 64Cu-TNYL-PEG-HAuNS (4.92% 
ID/g) in CT-26 tumors was significantly higher than 64Cu-PEG-HAuNS (1.49% ID/g) 
(P<0.001). The ratio of tumor-to-muscle in the mice injected with 64Cu-TNYL-PEG-
HAuNS (25.9) was four times higher than that in the mice injected with 64Cu-PEG-
HAuNS (6.2).  The ratio of tumor-to-blood in the mice injected with 64Cu-TNYL-PEG-
HAuNS (2.94) was 1.5 times higher than that in the mice injected with 64Cu-PEG-
HAuNS (2.0)  
 
Figure 22.  In vivo biodistribution and tumor uptake of 64Cu labeled TNYL-PEG-
HAuNS or PEG-HAuNS in mice bearing a CT-26 tumor, 24 h after intravenous injection. 
The mice bearing CT-26 tumor received 64Cu labeled TNYL-PEG-HAuNS light (light 
gray), or 64Cu labeled PEG-HAuNS (dark gray). 
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3.7 In Vivo Photothermal Therapy 
   Mice bearing CT-26 tumor were treated with TNYL-PEG-HAuNS, PEG-HAuNS 
(2x1012 per mouse, 200 µL) or saline (as control 200 µL). 24 h after injection, the tumors 
were treated with NIR irradiation. The skin at the tumor sites in mice that received 
intravenous injection of TNYL-PEG-HAuNS turned brownish, indicating tissue burns 
caused by the local photothermal effect. In contrast, there were less color changes 
(turned into a little white) in the skin of mice treated with PEG-HAuNS plus laser. There 
was no color changes in the skin of mice treated with saline plus NIR irradiation, or NIR 
laser alone (Figure. 23A). Histological examination of tissue slides cut from tumor 
confirmed that the intravenous injection of TNYL-PEG-HAuNS followed by laser 
treatment caused significantly greater thermonecrotic response than PEG-HAuNS plus 
laser treatment, saline plus laser treatment, or saline only did (Figure. 23B). In the mice 
treated with TNYL-PEG-HAuNS plus the laser, (Figures 23B and C), majority of tissues 
(82% of tissues) were necrotized, prominent features of thermonecrosis were found, such 
as karyolysis, cytoplasmic acidophilia, and corruption and degradation of the 
extracellular matrix of the tumor. Only a small fraction of the necrotic tissues (18.8% of 
tissues) was found in the tumor treated with PEG-HAuNS plus NIR laser (Figure 24) 
 
78 
 
 
 
Figure 23. AuNS nanoparticles can induce photothermal killing of CT-26 tumors in                  
vivo. (A) Photographs of tumor-bearing mice before and at after NIR laser irradiation 
(3W/cm2 at 808 nm for 5 min). (B) Representative microphotographs of tumors removed 
24 h after NIR laser treatment. The tissues were cryosectioned into 5 µm slices and 
stained with hematoxylin/eosin. Scale Bar, 500µm (C) Magnification of necrosis portion 
of tumor after laser treatment (red color) and normal part of tumor tissue after laser 
treatment (green color), Scale Bar=50µm. 
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Figure 24. The necrotic area as a percentage of the tumor is shown in the bar graph. * P 
< 0.005 (n = 4). 
 
4. Preliminary study to evaluate EphB4 specific peptide conjugated HAuNS for 
photothermal ablation therapy of ovarian cancer in vitro and vivo 
4.1 Expression of EphB4 receptors on Hey A8-Luc  
      In order to confirm the expression of EphB4 receptor in the Hey A8-Luc ovarian 
cancer cells, in vitro immunofluorescence study was performed. Figure 25 shows that 
EphB4 is expressed on the Hey A8-Luc cells compared with IgG control group.  
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Figure 25.  Fluorescence photomicrographs of HeyA8-Luc cells stained with rabbit anti-
human EphB4 1st antibody (1:100 dilution) and goat anti-rabbit 2nd antibody conjugated 
with Alexa Fluor 488 (1:500 dilution). Upper panel shows cells incubated with anti-
human EphB4 1st antibody and goat anti-rabbit 2nd antibody. Lower panel shows the 
results of IgG control group. 
 
 
4.2  In vitro photothermal ablation of Hey-A8 cancer cells 
Figure 26 shows that most of Hey A8-Luc cells treated with TNYL-PEG-HAuNS 
plus NIR laser irradiation (40 W/cm2 for 5 min) were not stained by calcein AM dye but 
stained for Eth-D1, which suggested that majority of cells were dead after NIR laser 
treatment. In contrast, cell viability has no changes after treatment of PEG-HAuNS plus 
laser, and laser only. The photothermal killing ability of TNYL-PEG-HAuNS was 
significantly abolished after adding excess amount of TNYL-PEG-SATA. 
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Figure 26.  Hey A8-Luc cells viability after various treatments. Most of cells were dead 
after treatment with TNYL-PEG-HAuNS plus NIR laser. Live cells were stained with 
calcein AM and dead cells were stained for Eth-D1.  Scale bar, 100 µm. 
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4.3 Detection of Hey-A8 tumor growth by luciferase imaging 
        14 days after Hey-A8-Luc tumor cells intraperitoneally implanted in nude mice, 
Tumor burden as measured by luciferase activity was assessed using Xenogen IVIS-200 
Optical in Vivo Imaging System. Figure 27 clearly showed the luciferase activity in the 
belly area of the nude mice in Hey-A8 tumor models, which confirmed that the tumors 
were successfully grown in the nude mice. 
 
Figure 27.  Representative Lucifease images of Hey-A8 tumor on intraperitoneal nude 
mice model. Figure 10 shows luciferase signal of Hey-A8-Luc 14 days after tail vein 
injection of luciferin. 
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4.4 In vivo biodistribution on intraperitoneal Hey-A8 ovarian tumor model 
      At 24 h after injection, uptake of 64Cu-TNYL-PEG-HAuNS (4.67% ID/g) in Hey-A8 
tumors was higher than 64Cu-PEG-HAuNS (3.4% ID/g) (P<0.005). The ratio of tumor-
to-muscle in the mice injected with 64Cu-TNYL-PEG-HAuNS was 11.67 compared with 
the mice injected with 64Cu-PEG-HAuNS (6.9).  The ratio of tumor-to-blood in the mice 
injected with 64Cu-TNYL-PEG-HAuNS (1.5) was almost the same as that in the mice 
injected with 64Cu-PEG-HAuNS (1.8).  
 
 
Figure 28. In vivo biodistribution and tumor uptake of 64Cu labeled TNYL-PEG-
HAuNS or PEG-HAuNS in mice bearing Hey-A8-Luc (intraperitoneal) tumor, 24 h after 
intravenous injection. The mice bearing Hey-A8-Luc tumor received 64Cu labeled 
TNYL-PEG-HAuNS light (red), or 64Cu labeled PEG-HAuNS (blue). 
 
 
 
 
 
4.5  In Vivo Photothermal Therapy in Hey-A8 ovarian cancer model 
       Mice bearing Hey-A8 tumor were treated with PEG-HAuNS (2x1012 per mouse, 200 
µL) or saline (as control 200 µL). 24 h after injection, the tumors were treated with NIR 
irradiation. The tumor received intravenous injection of PEG-HAuNS turned brownish, 
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indicating tissue burns caused by the local photothermal effect. There were no color 
changes in the tumor treated with saline plus NIR irradiation. The tumor treated with 
PEG-HAuNS plus the laser, (Figure 29), majority of tissues were necrotized, prominent 
features of thermonecrosis were found, such as karyolysis, cytoplasmic acidophilia, and 
corruption and degradation of the extracellular matrix of the tumor.  The structure of 
intestine surrounding tumors that were received photothermal treatment is intact, no 
significant thermal damage or necrosis was found on tissue slides. 
 
Figure 29.  AuNS nanoparticles can induce photothermal killing of Hey-A8 tumors in                  
vivo. (B) Representative microphotographs of tumor and intestine removed 24 h after 
NIR laser treatment. The tissues were cryosectioned into 5 µm slices and stained with 
hematoxylin/eosin. Scale Bar, 50µm  
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DISCUSSION 
In current study, we successfully developed EphB4 specific TNYL-RAW peptide 
and found that tail vein injection of the 64Cu labeled TNYL-RAW peptide allowed ready 
visualization of EphB4 positive tumor in different nude mice xenograft models by 
PET/CT. We also synthesized the dual-labeled 64Cu-TNYL-RAW-Cy5.5 peptides and 
evaluated the potential application of this peptide for micro PET/CT imaging and near 
infrared optical imaging in orthotopic glioblastoma (U87 and U251) mice models.  
Moreover, we synthesized EphB4 specific peptide TNYL-RAW conjugated hollow gold 
nanoshell for targeted micro PET imaging and photothermal ablation of EphB4-
overexpressing cancer cells in vitro and vivo. 
      EphB4 receptor has attracted a lot of interest in cancer imaging recently due to 
widespread overexpression of EphB4 receptor in lots of different tumors (93). It is 
possible to develop noninvasive imaging techniques to early diagnosis of patients with 
high expression of EphB4 receptors in their tumors or monitor the chemotherapy 
response of the tumors by using EphB4 receptor specific targeting agent.  For this 
purpose, we successfully synthesized and radiolabeled (64Cu) the EphB4 specific peptide 
TNYL-RAW for PET imaging based on the previous paper published peptide sequence 
(50). 
Based on the SPR analysis, the KD value of TNYL-RAW peptide was 3.09 nM, which 
is similar to the previous literature published (KD, 1–2 nM) (50). The slow dissociation 
rate of the TNYL-RAW peptide (~1.3x10-3 [s-1] strongly indicated that this peptide is 
suitable for in vivo molecular imaging applications due to its simple binding affinity. It 
has been reported that the stability of binding complex with EphB4 was not significantly 
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affected by modifying the N terminus of the peptide (94). However, based on our SPR 
analysis, it is interesting to find out that there was an 8-fold reduction in KD value of the 
TNYL-RAW when the N terminus of TNYL-RAW was modified by introducing the 
radiometal chelator DOTA. But the coupling of Cu2+ to the DOTA-TNYL-RAW peptide 
can restore the binding affinity of TNYLRAW to 1.89 nM (Table 1). Therefore, the 
subtle modification of N terminus of TNYL-RAW peptide can still affect the binding 
affinity of the TNYL-RAW to EphB4 receptors. Because there was no significant 
interaction between the scramble peptide and EphB4 receptors, we concluded that this 
TNYL-RAW binding to EphB4 in vitro is sequence specific.  In the literature, there has 
been reported that EphB4 receptors are overexpressed in most of colon cancer and 
prostate cancer cell lines (38, 95, 96). The CT26 (mouse colon cancer cell lines) and PC-
3M (human prostate cancer cell lines) cells used in our study has been confirmed 
positive for EphB4 expression (Figure 3) by immunofluorescence study. FITC labeled 
TNYL-RAW peptide exhibits high affinity and specific binding to EphB4 receptor in 
vitro binding study. The similar binding pattern to EphB4 positive cancer cells was also 
found in the results of 64Cu-DOTA-TNYL-RAW uptake study (Fig. 3 and 4).  The 
specific binding of peptide to EphB4 receptor was confirmed by in vitro blocking study. 
All above results indicated that 64Cu- DOTA-TNYL-RAW peptide is a suitable probe for 
noninvasive imaging of EPhB4 receptors.  
The uptake of 64Cu- DOTA-TNYL-RAW was significantly high in EphB4 positive 
PC-3M and CT-26 tumor xenografts in nude mice by in vivo micro PET/CT studies. In 
contrast, the radiotracer showed very low uptake in EphB4 negative A549 tumors at all 
time points examined (Fig. 5). To further confirm the expression status of EphB4 in 
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different tumors, ex vivo immunohistostaining of tumor xenografts sections was 
performed. The results showed that high expression level of EphB4 receptors was 
observed in both CT26 and PC-3M tumors but not in A549 tumors. From the micro 
PET/CT images, the radioactivity signal of 64Cu-DOTA-TNYL-RAW in CT26 tumors 
was significantly reduced after 4h post i.v. injection of radiotracer. In contrast, the signal 
of radioactivity reached highest in PC-3M tumors at 24 h post injection (Fig. 24). 
Because the relatively slow dissociation rate of peptide-EphB4 receptor complex, the 
major determinant of the difference in the signal intensity at various time points between 
those two tumors are the expression levels of EphB4 receptors on these two tumors. 
However, this different radiotracer retention time in tumor tissues between CT26 and 
PC-3M tumor mice models could also be explained by the difference in the degradation 
of 64Cu-DOTA-TNYL-RAW peptide–based radiotracer in different tumor 
microenvironments. It is very critical for maintaining the molecular integrity of the 
radioactive peptides in vivo condition in order to circulation in blood for the purpose of 
biodistribution and imaging studies. We tested the stability of 64Cu-DOTATNYL- RAW 
DMEM with 10% FBS and in mouse serum. We found out that it was stable in DMEM 
with 10% FBS for at least 24 h and in mouse serum for up to 2 h (Chiyi Xiong, et al. 
unpublished data). The slow degradation of peptide was observed in mouse serum after 2 
h incubation.  The above slow metabolic degradation of the radiolabeled peptide could 
be explained by the proteolysis of linear peptides by plasma peptidases present in mouse 
serum (97). In order to improve the stability of the peptide, we can introduce D-amino 
acid into the peptide sequence or cyclization  of the peptide to make it more resistant to 
enzymatic degradation (98, 99). The studies of improving in vivo stability of TNYL-
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RAW are in progress. Based on our stability data and in vivo PET/CT imaging results, 
the stability of our peptides is sufficient for in vivo applications of tumor imaging and 
biodistribution study. 
In order to confirm the specificity uptake of 64Cu- DOTA-TNYL-RAW in EphB4 
positive tumors in vivo, blocking studies were performed by co-administration of the 
radiolabeled peptides with excess amount of nonradioactive (cold) TNYL-RAW peptide. 
There were significant reductions in the uptake of 64Cu- DOTA-TNYL-RAW in both 
CT26 and PC-3M tumors with co-injection of radiotracer with excess amount of cold 
TNYL-RAW (Figure 5B) from micro PET/CT image results. Quantitative analysis of 
and comparison of radioactive uptake of 64Cu- DOTA-TNYL-RAW in different tumor 
tissues based on the ROI manually drawn from the micro PET/CT images showed that 
77% and 81% reduction in 64Cu-DOTA-TNYL-RAW uptake in CT-26 and PC-3M 
tumors at 4h or 24h respectively (Fig. 5B). The low uptake of 64Cu- DOTA-TNYL-
RAW (Figure. 5A) in EphB4 negative expression A549 tumors together with all above 
results supported conclusion that the specific uptake of 64Cu- DOTA-TNYL-RAW in 
EphB4 positive colon and prostate cancer xenografts in nude mice models was mediated 
by EphB4 receptors. The biodistributions of 64Cu-DOTA-TNYL-RAW in different 
tumor models obtained by both noninvasive PET/CT calculated from ROI and by in vivo 
tissue sampling indicated that the major organs for uptake and clearance of this 
radiopharmaceutical were in liver and the kidney.  It was well known that the major 
organ for clearance of hydrophobic peptides is in liver (100). The high level of uptake of 
64Cu-DOTA-TNYL-RAW in liver could be attributed to compositions of the 
hydrophobic amino acids (Asn, Ile, Leu, Phe, Pro, Ala, Trp) in TNYL-RAW peptides. 
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Also the significant uptake of the radiotracers in the nude mice kidneys was due to the 
degradation of the peptide by lysosome within renal cells (101). Therefore, it is 
important for us to optimize pharmacokinetics and in vivo stability of peptides for in vivo 
imaging applications. 
      Glioblastoma is the most malignant primary brain tumor that is resistant to most of 
common drug therapies. The frequent recurrence of this tumor is due to its infiltration 
into surrounding normal brain tissue and difficulty in complete resection of the tumors 
(102, 103). It is important to develop diagnostic imaging agent to monitor tumor growth 
in the brain and evaluate tumor responses to therapeutic drugs. Recently, lots of optical 
imaging using near infrared fluorescent dye labeled tumor-specific molecules has been 
successfully applied to imaging glioma in preclinical animal models based on the 
overexpression of specific marker on glioma (104-106).  The characteristics of  near 
infrared fluorescence (NIR) such as long wavelength (650–900 nm), lower light 
absorbance and scattering, and reduced autofluorescence of normal tissues make it great 
potential in clinical imaging application (107). Several recent studies have demonstrated 
that using fluorescence imaging to improve radical resection of GBM during surgery 
(108-110). Meanwhile, nuclear imaging has high detection sensitivity ability, which 
makes it especially suitable for tracking radiotracers used in in vivo molecular imaging.  
So, it is highly desirable to develop an imaging probe combining a radioisotope and a 
near-infrared fluorescent dye for dual nuclear and optical imaging of glioma. 
Overexpression of EphB4 receptors has been reported in a number of tumors. Up to now, 
there are few papers describing the applications of EphB4 as target for cancer imaging 
(35, 36). In high-grade glioma, EphB4 are expressed at high levels in both tumor cells 
90 
 
and blood vessels16. In current study, we developed dual-labeled EphB4 specific TNYL-
RAW peptides for visualization of glioblasotomas with micro PET/CT and near-infrared 
fluorescence imaging on orthotopic mice model.  
    SPR analysis showed that the KD values of Cy5.5-TNYL-RAW and Cy5.5-TNYL-
RAW-DOta are around 1nM which have no significant changes compared with the value 
of original TNYL-RAW peptide (3.07 nM). The high binding affinity of the dual labeled 
EphB4 specific peptide to EphB4 receptor in vivtro makes it suitable for in vivo 
molecular imaging application. For monitor intracranial tumor growth in nude mice, we 
made the stable cell lines that express the luciferase gene. Ten days post injection of 
tumors in the mice brains, the detectable luciferase signal has been visualized on 
Xenogen imaging system which corresponded to the tumor growth in the mice brain. 
Near infrared fluorescence imaging studies revealed that Cy5.5-TNYL-RAW-DOTA has 
significant higher uptake in U251 and u87 tumors in orthotopic nude mice model. To 
confirm the specificity of uptake of EphB4 targeted peptide in tumors, Cy5.5 labeled 
scramble peptides have been used. From various time points of optical imaging, it 
clearly showed that there was low uptake of scramble peptides uptake in U87 tumors 
compared with that of Cy5.5-TNYL-RAW-DOTA peptides, which indicated that this 
high uptake of EphB4 peptides into tumors was mediated through EphB4 receptor 
(Figure 11B). The biodistribution data showed the same result as fluorescence optical 
imaging based on ex vivo analysis of the fluorescence signal intensities of dissected 
tissues.  High fluorescence activity was found in mice liver, kidney, stomach and 
intestine.  Compared with fluorescence densities in two groups at different time points, it 
clearly showed that U87 tumor has significantly higher uptake of Cy5.5-TNYL-RAW-
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DOTA than that of Cy5.5-scramble-DOTA (Figures 12A and 12B). It is interesting to 
notice that the accumulation of Cy5.5-TNYL-RAW-DOTA was lower in liver than that 
in kidney, but the uptake of 64Cu-TNYL-RAW was similar in both kidney and liver in 
previous results. This phenomenon maybe due to the underestimation of the fluorescence 
signal obtained from liver. Previous paper published in our lab (111) demonstrated that 
ex vivo analysis fluorescence intensity may have underestimated the uptake of 
nanoparticles or compounds in organs with high blood perfusion. Because estimation of 
uptake of compounds in tissues based on fluorescence intensity is less accurate the 
radioactivity count method, our above data suggested that the biodistribution data should 
be corrected in different organs when fluorescence method is used. 
   Micro PET/CT images revealed significant high uptake of 64Cu labeled Cy5.5-
TNYL-RAW-DOTA peptides in U251 and in U87 tumor models.  The intensity of 
radioisotope labeled peptides was greatly reduced in U251 tumors after co-injection of 
excess amount of cold peptide with the 64Cu labeled Cy5.5-TNYL-RAW-DOTA 
peptides (Figures 13A and 13B). Quantitative analysis of micro PET/CT imaging 
revealed that In U251 tumor models, the co=administration of cold Cy5.5-TNYL-RAW-
DOTA caused a 57% reduction in the ratio of 64Cu-Cy5.5-TNYLRAW-DOTA 
accumulation in tumors versus normal brain, which demonstrated the specific uptake of 
dual labeled TNYL-RAW-DOTA peptide in U251 tumor. Immunofluorescence 
microscope study showed an interesting phenomenon. For U251 tumor model, Cy5.5 
labeled peptides mainly bind to tumor cells and tumor associated vessels which both 
express EphB4 receptor on their surface. In contrast, the Cy5.5 labeled peptides only 
bind to tumor associated vessel that express EphB4 but not on tumor cells that is 
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negative staining for the expression of EpHB4 (Figure 14). It has been reported that 
EphB4 are overexprerssed on brain tumor cells and tumor associated vessels. This is the 
first time we show here that the new developed dual-labeled EphB4-specific peptide 
could be used as a non-invasive molecular imaging agent for PET/CT and optical 
imaging of glioma owing to its ability to bind to EphB4-expressing angiogenic blood 
vessels and/ or to EphB4-expressing tumor.  
     HAuNS have already shown the great potential in photothermal therapy of cancer 
due to their unique characteristics such as small size (30-60 nm), spherical shape, and 
hollow interior and strong tunable (520-950nm) absorption band (74). The further 
application of the HAuNS to cancer therapy is to develop targeted delivery of 
nanoparticles into tumors to minimize the thermal damage to surrounding normal tissues. 
With this aim, we developed TNYL-conjugated HAuNS for selective photothermal 
killing of EphB4 positive cancer cells. In current study, we successfully conjugate 
EphB4 specific (TNTL-PEG) peptide and/or PEG-SH onto the surface of HAuNS 
without significant changes of the properties of HAuNS. From resonance absorbance 
curves, the absorption peak of the TNYL-PEG-HAuNS or PEG-HAuNS is still around 
800nm compared with original HAuNs, which demonstrates that conjugation of peptides 
onto the surface of HAuNS has no obvious effect on the plasma resonance property. The 
temperature of nanoparticle solutions was increased from 27 ºC to 75 ºC at the 
concentration of 4x1011 particles/mL after exposure to near infrared-region laser light. 
The photothermal effect of these particles remains no changes after conjugation of 
peptides. The amount of peptides on the surface of HAuNS will also affect the specific 
binding affinity of HAuNS to EphB4 positive tumors. From our amino acid analysis of 
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conjugated HAuNS, the number of peptides on the surface of HAuNS is around 40, 
which will greatly increase the binding repertoire of original TNYL-PEG peptide. As 
shown in Figures 16, TNYL-PEG-HAuNS but not PEG-HAuNS binds to EphB4 
positive PC-3M and CT-26 cells. Moreover, the uptake of TNYL-PEG-HAuNS to CT-
26 or PC-3M cells could specifically be blocked by excess amount of free TNYL-PEG 
peptides, indicating that TNYL-PEG-HAuNS was taken up by the PC-3M or CT-26 cells 
through EphB4 receptor-mediated.  After exposure CT-26, PC3-M or Hey-A8 cells 
treated with TNYL-PEG-HAuNS or PEG-HAuNS to NIR laser at 40W/cm2 for 5 min, 
almost majority of cancer cells treated with TNYL-PEG-HAuNS were destroyed after 
exposure to laser, but this effect was not observed in cells exposed NIR laser alone or 
PEG-HAuNS plus laser group. This photothermal killing effect was efficiently abolished 
by the addition of excess amount of PEG-TNYL peptide into the reaction.  
     For in vivo active targeting nanoparticles to the tumor tissue, HAuNS must be capable 
of extravasating into the tumor interstitial space. Our HAuNS with small size makes it 
suitable for in vivo delivery to tumor site. The photothermal effect of HAuNS in vivo 
depends on the number of particle actively taken up by the tumor. To quantify the 
amount of nanopaticles specific delivery to EphB4 positive CT-26 tumors in vivo after 
systematic administration of 64Cu-TNYL-PEG-HAuNS or 64Cu-PEG-HAuNS, micro-
PET and in vivo biodistribution experiments were performed. From Figure 21, it clearly 
showed that the tumor was visualized at 1 hour after the injection and the signal was 
strongest at 24 h post injection. But low signal in the tumors of mice injected with 64Cu-
PEG-HAuNS was also observed, which suggested that non-specific uptake of HAuNS in 
the tumor tissue. This nonspecific uptake phenomenon can be explained by the EPR 
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(enhanced permeability and retention) effect. The EPR effect is the property by witch 
that certain size of the molecules such as liposomes, nanoparticles and some 
macromolecules can accumulate into the tumor tissue much more than they do in normal 
tissues due to the pathophysiological changes of tumor vessels (extensive angiogenesis 
defective vascular architecture, and greatly increased production of permeability 
mediators) (112-115).  The biodistribution study also showed the similar results to the 
micro-PET imaging study. At 24 h after injection of radiolabeled nanoparticles, uptake 
of 64Cu-TNYL-PEG-HAuNS was significantly higher (4.92% ID/g) in CT-26 tumors 
than that of 64Cu-PEG-HAuNS was. (1.49% ID/g) (p<0.001). The tumor-to-muscle ratio 
was 6.2 in the mice injected of 64Cu-PEG-HAuNS, while it was 25.9 in the mice treated 
with 64Cu-TNYL-PEG-HAuNS. Also the The ratio of tumor-to-blood in the mice 
injected with 64Cu-TNYL-PEG-HAuNS (2.94) was 1.5 times higher than that in the mice 
injected with 64Cu-PEG-HAuNS (2.0) (p<0.005). Taken together, all above data 
demonstrate that TNYL-PEG-HAuNS can be specifically uptake into EphB4 positive 
CT-26 tumors compared with control PEG-HAuNS. (Figure 22). In vivo photothermal 
therapy study confirmed that tumor with intravenous injection of TNYL-PEG-HAuNS 
plus laser treatment caused significantly greater thermonecrotic response than that of 
mice treated with PEG-HAuNS plus laser treatment, saline plus laser treatment, or saline 
only (Figs. 23B and 23C). In the mice treated with TNYL-PEG-HAuNS plus the laser, 
(Figures 23B and C), majority of tissues (82% of tissues) were necrotized, prominent 
features of thermonecrosis were found, such as karyolysis, cytoplasmic acidophilia, and 
corruption and degradation of the extracellular matrix of the tumor. Only a small fraction 
of the necrotic tissues (18.8% of tissues) was found in the tumor treated with PEG-
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HAuNS plus NIR laser (Figure 24). From histological results, we still can observe some 
necrosis response in PEG-HAuNS plus laser treatment group, which also can be 
explained by EPR effect witch corresponding to the result of micro-PET and 
biodistribution data. Our current study clearly shows the selective killing tumor cells 
after intravaneously injection of TNYL-PEG-HAuNS plus near infrared-region laser 
light treatment. But the tumor model we choose here is subcutaneous tumor model 
which may not reflect the real situation due to the local blood flow difference between 
subcutaneous of the mouse skins and orthotropic sites.  
Therefore, further studies will focus on the application of TNYL-PEG-HAuNS in 
orthotropic tumor models for further investigation of their photothermal killing effect in 
vivo. But the study of biodistribution of 64Cu-TNYL-PEG-HAuNS or 64Cu-PEG-HAuNS 
on Hey-A8-Luc ovarian cancer intraperitoneal nude mice models showed that the uptake 
of 64Cu-TNYL-PEG-HAuNS was statistically higher (4.67% ID/g) in Hey-A8 tumors 
than that of 64Cu-PEG-HAuNS was (3.4% ID/g) (P<0.005).  But the ratio of tumor-to-
blood in the mice injected with 64Cu-TNYL-PEG-HAuNS (1.5) was almost the same as 
that in the mice injected with 64Cu-PEG-HAuNS (1.8), which suggested that the 
different uptake of 64Cu-TNYL-PEG-HAuNS and 64Cu-PEG-HAuNS in the Hey-A8 
tumors may be due to the EPR effect. Although we didn’t get promising data from 
orthotopic ovarian cancer models, it still provided us useful information. In clinical 
situation, it is very difficult to treat metastatic spread of ovarian cancer in pelvic of 
patients. Because we didn’t find good targeting effect of TNYL-PEG-HAuNS on Hey-
A8 nude mice model, we want to study the photothermal killing effect of PEG-HAuNS 
on tumors after intraveneously injection of the nanoparticles due to the high uptake of 
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the 64Cu-PEG-HAuNS (3.4%) in tumor. After treating the tumor with laser at 2W/cm 2, 
the color of the tumor of the mice injected with PEG-HAuNS turned into brown color, 
but there is no color change of the tumor with saline injected or with no treatment. H&E 
staining results showed that majority of tissues were necrotized, prominent features of 
thermonecrosis were found, such as karyolysis, cytoplasmic acidophilia, and corruption 
and degradation of the extracellular matrix of the tumor. For saline control or no 
treatment group, there was no thermonecrosis area in the tumor section. To check 
whether the laser treatment will damage the local normal tissue surrounding the tumor, 
the intestine tissues around the tumor were also taken out and cut into sections. We can 
see that the structure of intestine was still intact and there is no photothermal damage to 
the normal intestine tissues so far. It is still preliminary data for investigation of 
photothermal effect on Hey-A8 intraperitoneal ovarian cancer model. In  the future, we 
need test this killing effect on more mice to collect data to figure out whether this local 
photothermal effect will kill tumor cells but cause no or minimum damage to the tissue 
surrounding it. Because we only tested our nanoparticles on one ovarian orthotopic 
model, we still need check other orthotopic ovarian cancer models such as transgenic 
mice models to further investigate the targeting effect of TNYL-PEG-HAuNS in vivo. 
    Though TNYL-RAW showed a great potential in the application of imaging tumor in 
mice and cancer thermal therapy when conjugated with HAuNS, there is a still long way 
to go before we apply it in clinical use. First, the slowly degradation of TNYL-RAW in 
mouse serum indicates that the detection sensitivity will decrease after long time 
circulation in the body. It is important to improve the stability of this peptide for its 
clinical application. Introduction of D-amino acid or cyclization of peptide can make it 
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more resistant to proteolytic degradation of peptide. Now we have already synthesized 
the second generation of the peptides to optimize the stability of the peptide. Our SPR 
analysis confirmed that introduction of D-amino acid into peptide sequence or 
cyclization of the peptide did not significantly change the binding affinity of the peptide 
to EphB4 receptor. In the future, we will evaluate its application in tumor imaging in 
vivo by micro PET/CT or optical imaging. Secondly, it is obvious that the major organ 
for the clearance of the peptide is liver. So it is highly desirable to modify the structure 
of the peptide to reduce the liver clearance.  Literature has been reported that pegylation 
of the peptide can significantly reduce the liver nonspecific uptake of the peptide (116, 
117). Synthesis and evaluation of the PEG conjugated TNYL-RAW in vivo PET/CT 
imaging of tumor on nude mice is ongoing right now. Third, the tumor model we used in 
this study for evaluate the peptide is subcurtaneously model and brain orthotopic models, 
which is not the most ideal models for evaluation of peptide in vivo applications due to 
difference in the local blood flow and microenviroment for tumor growth. There are lots 
of transgenic mice tumor models available for prostate, colon and glioma cancers. We 
will evaluate our peptide in these transgenic mice models for in vivo molecular imaging 
applications. Conjugation of TNYL-RAW peptide onto the surface of the HAuNS makes 
it suitable for targeting photothermal therapy. In this study we only use microscopic 
study to evaluate necrotic response of photothermal therapy, which is not very accurate. 
So it is highly desirable use other methods to evaluate tumor necrosis induced by 
photothermal therapy. Our lab has developed 64Cu-DOTA-hypericin for evaluation of 
the tumor necrosis induced by photothermal therapy by PET/CT (118). Also 18F-FDG 
can also be used to monitor the changes of metabolic activity of the tumors by micro 
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PET/CT (85).We can use above methods to monitor tumor response to the photothermal 
therapy for EphB4 conjugated HAuNS. To monitor the tumor response to the 
photothermal therapy, we can also monitor the tumor growth in long term after treatment 
to see whether tumor growth can be inhibited by photothermal therapy. Because in 
clinical settings, it is very difficult to remove all of the metastatic nodules in the pelvic 
of ovarian cancer patients by surgery, it is very desirable to find alternative way to treat 
this advanced stage disease to avoid using aggressive surgery treatment. Using 
photothermal ablation therapy, the tumor can shrink and necrotized. So it is important 
for us to study the photothermal effect of HAuNS on more ovarian cancer nude mice 
models in future. 
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CONCLUSIONS 
  In the current study, it is the first time to visualize tumor by in vivo noninvasive 
micro PET/CT using EphB4 specific radiotracer 64Cu- DOTA-TNYL-RAW. This 
radiolabeled peptide could be used for early diagnosis of patients with high expression of 
EphB4 receptors in their tumors or monitoring the chemotherapy response of the tumors. 
To demonstrate the future potential of this radiotracer, it is important for us to evaluate it 
in additional animal models and ex vivo human specimens. We also evaluated the 
potential applications of 64 Cu and Cy5.5 dual labeled TNYL-RAW-DOTA peptides for 
micro PET/CT imaging and near infrared optical imaging in orthotopic glioblastoma 
mice model. µPET/CT and near-infrared optical imaging clearly showed the uptake of 
the dual labeled TNYL-RAW peptide in both U251 and U87 tumors in the brains of 
nude mice after intravenous injection. The specific uptake of dual labeled peptide in both 
tumors was confirmed by blocking experiments. In U87 tumors, Cy5.5-labeled peptide 
was found co-localized only with CD31- and EphB4-expressing tumor blood vessels. 
Dual-labeled EphB4-specific peptide could be used as a non-invasive molecular imaging 
agent for PET/CT and optical imaging of glioma owing to its ability to bind to EphB4-
expressing angiogenic blood vessels and to EphB4-expressing tumor. We developed the 
EphB4 specific peptide conjugated HAuNS for micro PET imaging and photothermal 
ablation of EphB4-overexpressing cancer cells in vitro and vivo. TNYL-PEG-HAuNS 
targeted to EphB4 receptor have been shown to selectively bind to EphB4-positive 
cancer cells (PC-3M and CT-26) and destroy these cells via a photothermal effect in 
vitro. EphB4-positive CT-26 tumors were clearly visualized with 64Cu-labeled TNYL-
PEG-HAuNS. In vivo biodistribution study, up to 4.9.%ID/g of 64Cu-labeled TNYL-
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PEG-HAuNS was taken up by CT-26 tumor compared to TNYL-HAuNS. EphB4 
targeted TNYL-PEG-HAuNS shows more photothermal killing effect on CT26 tumor 
models than PEG-HAuNS do, which suggests that TNYL-PEG-HAuNS targeting to 
EphB4 receptor may have future applications in photothermal ablation therapy in 
clinical.  
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